51
|
Nishikawa D, Sasaki E, Suzuki H, Beppu S, Sawabe M, Terada H, Sone M, Hanai N. Treatment outcome and pattern of recurrence of sinonasal squamous cell carcinoma with EGFR-mutation and human papillomavirus. J Craniomaxillofac Surg 2021; 49:494-500. [PMID: 33676817 DOI: 10.1016/j.jcms.2021.02.016] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 01/23/2021] [Accepted: 02/18/2021] [Indexed: 02/03/2023] Open
Abstract
The objective of our study was to clarify the clinical features of EGFR-mutated sinonasal squamous cell carcinoma (SNSCC) and human papilloma virus (HPV)-related SNSCC. Patients with SNSCC treated from April 2008 to June 2019 at our institution were retrospectively reviewed. We examined EGFR mutation and HPV status for all patients. Main outcomes were overall survival, recurrence, and outcome of each treatment modality. A total of 85 patients with SNSCC were enrolled in this study. EGFR mutations and HPV DNA were detected in 24 (28%) and 7 (8%) patients, respectively. Patients with EGFR-mutated SNSCC showed a worse overall survival (OS) than those with EGFR wild-type in the multivariate analysis (p = 0.037). No death was observed in HPV-positive SNSCC. The cumulative incidence of local recurrence was significantly higher in EGFR mutant than EGFR wild-type tumors (p = 0.03). In patients with EGFR mutations, treatment with induction chemotherapy significantly improved OS (p = 0.01). EGFR-mutated SNSCC have a high-risk feature for recurrence and requires intensive attention for treatment and observation. A new treatment approach, such as EGFR tyrosine kinase inhibitors, may be needed.
Collapse
Affiliation(s)
- Daisuke Nishikawa
- Department of Head and Neck Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan; Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, 65-banchi, Tsurumai-cho, Showa-ku, Nagoya-shi, Aichi, Nagoya, Japan.
| | - Eiichi Sasaki
- Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Nagoya, Japan.
| | - Hidenori Suzuki
- Department of Head and Neck Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan.
| | - Shintaro Beppu
- Department of Head and Neck Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan.
| | - Michi Sawabe
- Department of Head and Neck Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan.
| | - Hoshino Terada
- Department of Head and Neck Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan.
| | - Michihiko Sone
- Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, 65-banchi, Tsurumai-cho, Showa-ku, Nagoya-shi, Aichi, Nagoya, Japan.
| | - Nobuhiro Hanai
- Department of Head and Neck Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan.
| |
Collapse
|
52
|
Saba NF. Preoperative chemotherapy for sinonasal squamous cell carcinoma (SNSCC): Time to move closer to a definitive answer. Cancer 2021; 127:1734-1735. [PMID: 33567473 DOI: 10.1002/cncr.33450] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 12/29/2020] [Accepted: 01/04/2021] [Indexed: 01/02/2023]
Affiliation(s)
- Nabil F Saba
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia
| |
Collapse
|
53
|
Abdelmeguid AS, Teeramatwanich W, Roberts DB, Amit M, Ferraroto R, Glisson BS, Kupferman ME, Su SY, Phan J, Garden AS, Raza SM, DeMonte F, Hanna EY. Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. Cancer 2021; 127:1788-1795. [PMID: 33567468 DOI: 10.1002/cncr.33452] [Citation(s) in RCA: 35] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Revised: 10/27/2020] [Accepted: 11/11/2020] [Indexed: 12/31/2022]
Abstract
BACKGROUND Squamous cell carcinoma is the most common type of sinonasal malignancy. Despite improvements in surgical resection and adjuvant therapy, which are considered the standard of care, the outcome for patients with locoregionally advanced disease remains poor. The objective of this study was to investigate the role of induction chemotherapy in patients with locoregionally advanced sinonasal squamous cell carcinoma and to determine the oncologic outcomes in those patients. METHODS The study included 123 consecutive patients with previously untreated, locoregionally advanced (stage III and IV) sinonasal squamous cell carcinoma who were treated with curative intent at The University of Texas MD Anderson Cancer Center between 1988 and 2017 with induction chemotherapy followed by definitive local therapy. Patient demographics, tumor staging, treatment details, and oncologic outcomes were reviewed. The outcomes of this study included response to induction chemotherapy, recurrence, organ preservation, and survival. RESULTS The median follow-up was 32.6 months (range, 12.4-240 months). Of the 123 patients, 110 (89%) had T4 disease, and 13 (11%) had T3 disease. Lymph node metastasis at the time of presentation was observed in 36 patients (29.3%). The overall stage was stage IV in 111 patients (90.2%) and stage III in 12 patients (9.8%). The chemotherapy regimen consisted of the combination of a platinum and taxanes in most cases (109 patients; 88.6%), either as a doublet (41 patients) or in combination with a third agent, such as 5-fluorouracil (34 patients), ifosfamide (26 patients), or cetuximab (8 patients). After induction chemotherapy, 71 patients (57.8%) achieved at least a partial response, and 6 patients had a complete response. Subsequent treatment after induction chemotherapy was either: 1) definitive chemoradiation or radiation followed by surgical salvage for any residual disease, or 2) surgery followed by adjuvant radiation or chemoradiation. Overall, 54 patients (49.5%) underwent surgical resection. The 2-year overall and disease-free survival rates for the whole cohort were 61.4% and 67.9%, respectively. The rate of orbital preservation was 81.5%. The recurrence rate was 26.8% (33 patients), and distant metastases occurred in 8 patients (6.5%). Patients who had at least a partial response or stable disease had significantly better overall and disease-free survival than those who had progressive disease (P = .028 and P = .021, respectively). CONCLUSIONS The current results indicate that a high proportion of patients with sinonasal squamous cell carcinoma achieved a favorable response to induction chemotherapy. The data suggest that response to induction chemotherapy is associated with an improved outcome and a good chance of organ preservation. The oncologic outcomes in this cohort with locally advanced (mostly T4) disease are better than those historically reported in the literature. Further study of induction chemotherapy in patients with advanced sinonasal squamous carcinoma is warranted.
Collapse
Affiliation(s)
- Ahmed S Abdelmeguid
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.,Department of Otolaryngology Head and Neck Surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt
| | | | - Dianna B Roberts
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Moran Amit
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Renata Ferraroto
- Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Bonnie S Glisson
- Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Michael E Kupferman
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Shirley Y Su
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Jack Phan
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Adam S Garden
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Shaan M Raza
- Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Franco DeMonte
- Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Ehab Y Hanna
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
| |
Collapse
|
54
|
Tseng CC, Gao J, Barinsky GL, Fang CH, Grube JG, Eloy JA, Hsueh WD. Extranodal Extension as an Indicator for Sinonasal Squamous Cell Carcinoma Prognosis. Otolaryngol Head Neck Surg 2021; 165:438-445. [PMID: 33557716 DOI: 10.1177/0194599820987469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Although extranodal extension (ENE) is a known indicator of poor prognosis for head and neck malignancies, its value as an indicator for sinonasal squamous cell carcinoma (SCC) has not been well characterized. This study seeks to assess the usefulness of ENE as a prognostic marker for sinonasal SCC. STUDY DESIGN Retrospective database review. SETTING National Cancer Database from 2010 to 2015. METHODS The National Cancer Database was queried from 2010 to 2015 for all patients with sinonasal SCC with available ENE status (n = 355). These cases were divided into those with pathologically confirmed ENE (n = 146) and those without ENE (n = 209). Univariate and multivariate analyses were used to examine survival differences and predictors of ENE status. RESULTS Most patients with ENE were ≥60 years old (61.7%), male (61.6%), and white (83.6%). Patients aged 60 to 69 and 80+ years were more likely to have ENE than those under 60 years (P < .05). Patients with ENE had worse 1-year overall survival than those without ENE (58.2% vs 70.8%, log-rank P = .008). After multivariate regression, however, there was no survival difference detected between ENE-positive and ENE-negative cases (hazard ratio, 1.14 [0.775-1.672], P = .508). CONCLUSION ENE status did not have a significant effect on survival in patients with sinonasal SCC. Thus, ENE alone may not necessarily be a helpful indicator for sinonasal SCC prognosis.
Collapse
Affiliation(s)
- Christopher C Tseng
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA
| | - Jeff Gao
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA
| | - Gregory L Barinsky
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA
| | - Christina H Fang
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA
| | - Jordon G Grube
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA
| | - Jean Anderson Eloy
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.,Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey, Rutgers New Jersey Medical School, Newark, New Jersey, USA.,Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.,Department of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, USA
| | - Wayne Daniel Hsueh
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.,Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey, Rutgers New Jersey Medical School, Newark, New Jersey, USA
| |
Collapse
|
55
|
Clinicopathologic Significance of EGFR Mutation and HPV Infection in Sinonasal Squamous Cell Carcinoma. Am J Surg Pathol 2021; 45:108-118. [PMID: 32868526 DOI: 10.1097/pas.0000000000001566] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Sinonasal squamous cell carcinoma (SNSCC) is sometimes associated with high-risk human papillomavirus (HR-HPV) infection and inverted sinonasal papilloma or oncocytic sinonasal papilloma. Frequent mutations of EGFR and KRAS are reported in inverted sinonasal papilloma-related sinonasal squamous cell carcinoma (ISP-SCC) and oncocytic sinonasal papilloma-related SNSCC, respectively. Here, we attempted to determine the prevalence and the prognostic significances of these alterations in SNSCC. We retrospectively collected 146 SNSCCs, including 14 ISP-SCCs, and comprehensively analyzed the HR-HPV infection by human papillomavirus (HPV)-RNA in situ hybridization, EGFR gene copy number gain (CNG) by chromogenic in situ hybridization, and gene mutations in EGFR and KRAS by Sanger sequencing. HR-HPV was detected in 11 cases (7.5%), whereas all 14 ISP-SCCs were negative. EGFR mutations were present in 21 (14.7%) of 143 SNSCCs, including 13/14 (92.9%) ISP-SCCs and 8/129 (6.2%) non-ISP-SCCs (P<0.0001). The majority of EGFR mutations were exon 20 insertions, with the remainder composed of deletions and single-nucleotide substitutions in exons 19 and 20. All of 142 SNSCCs harbored no KRAS mutation. EGFR CNG was detected in 41 (28.1%) of 146 SNSCCs; all of them were HPV negative and 3 had EGFR mutations. Collectively, EGFR mutation, EGFR CNG, and HR-HPV were essentially mutually exclusive, and each subgroup had distinct clinicopathologic features. The HPV-negative/EGFR-mutant group, the HPV-negative/EGFR CNG-positive group, and the triple-negative group had significantly worse prognoses than the HPV-positive group (P=0.0265, 0.0264, and 0.0394, respectively). In conclusion, EGFR mutation may play a pathogenetically important role in some populations of SNSCCs, especially ISP-SCCs. The molecular subclassification of SNSCCs may contribute to prognostic prediction and molecular-targeted precision medicine.
Collapse
|
56
|
Rajendran B. Surgical outcomes of endoscopic versus open resection for the management of sinonasal malignancies. J Korean Assoc Oral Maxillofac Surg 2020; 46:373-378. [PMID: 33377461 PMCID: PMC7783184 DOI: 10.5125/jkaoms.2020.46.6.373] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2020] [Revised: 09/13/2020] [Accepted: 10/05/2020] [Indexed: 11/07/2022] Open
Abstract
The purpose of this review is to assess the surgical outcomes of two different treatment modalities, endoscopic and open resection, for the management of sinonasal malignancies by comparing the effectiveness of these two methods. A wide search was carried out considering various electronic databases for English language articles from 2013 to 2018 using keywords such as sinonasal malignancies, endoscopic surgery, open resection for sinonasal malignancies, and endoscopic versus open surgery. One thousand articles were identified from the literature for screening. After a thorough systematic assessment and based on the selection criteria, 10 articles with 4,642 patients were included in this quantitative analysis. With a total of 4,642 patients, 1,730 patients were operated on using endoscopic resection and 2,912 patients were operated on using open resection. The endoscopic approach was found to have a shorter hospital stay compared to open surgical resection (P<0.05). The rate of positive margins and the recurrence rate for open surgical resection were both smaller compared to those for endoscopic resection (P>0.05), and the endoscopic approach had smaller complication rates and a higher survival rate compared to open resection (P>0.05). Though endoscopic resection and open surgical resection have comparable postoperative benefits, preoperative evaluation of cases presenting with sinonasal malignancies is necessary for determining the right treatment method to obtain the best possible results postoperatively.
Collapse
Affiliation(s)
- Balamurugan Rajendran
- Oral and Maxillofacial Surgeon and Oral Implantologist, RYA Cosmo Foundation, Chennai, India
| |
Collapse
|
57
|
Mikhael ST, Tadrosse AF, Tadrosse MF, Yassa A, Mikhael MT, Barinsky GL, Grube JG, Fang CH, Eloy JA. Geographic and Socioeconomic Factors on Survival in Esthesioneuroblastoma. Laryngoscope 2020; 131:E2162-E2168. [PMID: 33347619 DOI: 10.1002/lary.29228] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2020] [Revised: 10/17/2020] [Accepted: 10/21/2020] [Indexed: 01/16/2023]
Abstract
OBJECTIVES Esthesioneuroblastoma (ENB) is a rare sinonasal malignancy with little known regarding how regional and socioeconomic differences in the United States alter disease survival. The aim of this study is to explore the geographic difference in clinical features, socioeconomic factors, and survival outcomes of ENB patients. METHODS ENB cases were extracted from the Surveillance, Epidemiology, and End Results registry from 1975-2016. Patient data were stratified based on geographical location and comparative analyses of socioeconomic features, disease characteristics, and survival patterns were performed. Kaplan-Meier regression analyses were used to estimate disease-specific survival (DSS). RESULTS A total of 987 patients were identified: 56.4% West, 14.0% South, 12.7% Midwest, and 16.6% East. The West had the highest proportion of patients with Medicaid coverage (P < .001), stage A malignancy (P < .001), and treated with surgery and adjuvant radiotherapy (P < .001). The South had the highest proportion of patients who were Black (P < .001), uninsured (P < .001), and resided in rural areas (P < .001). Five-year DSS patterns were 81.0% (West), 79.8% (East), 67.4% (Midwest), and 72.7% (South) [P = .018]. Ten-year DSS outcomes were 74.0% (West), 73.7% (East), 60.9% (Midwest), and 63.6% (South) [P = .017]. CONCLUSION In ENB patients, survival disparity exists in the United States based on geographical region. Patients from the West and East exhibit higher survival than those from the South and Midwest. LEVEL OF EVIDENCE 4 Laryngoscope, 131:E2162-E2168, 2021.
Collapse
Affiliation(s)
- Sandra T Mikhael
- Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, U.S.A
| | - Abanoob F Tadrosse
- Department of Otolaryngology - Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A
| | - Marina F Tadrosse
- Department of Otolaryngology - Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A
| | - Arsany Yassa
- Department of Otolaryngology - Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A
| | - Mina T Mikhael
- Department of Otolaryngology - Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A
| | - Gregory L Barinsky
- Department of Otolaryngology - Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A
| | - Jordon G Grube
- Department of Otolaryngology - Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A
| | - Christina H Fang
- Department of Otolaryngology - Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A
| | - Jean Anderson Eloy
- Department of Otolaryngology - Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.,Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.,Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.,Department of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.,Department of Otolaryngology and Facial Plastic Surgery, Saint Barnabas Medical Center - RWJBarnabas Health, Livingston, New Jersey, U.S.A
| |
Collapse
|
58
|
Forner D, Horwich P, Trites JR, Hollenhorst H, Bullock M, Lamond NWD. The abscopal effect in head-and-neck squamous cell carcinoma treated with radiotherapy and nivolumab: a case report and literature review. Curr Oncol 2020; 27:330-335. [PMID: 33380865 PMCID: PMC7755449 DOI: 10.3747/co.27.6687] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Introduction The abscopal effect is a rarely observed outcome of radiotherapy wherein there is a reduction in metastatic disease burden outside of the targeted treatment area. Likely due to an in situ vaccine effect of radiotherapy, the abscopal effect may be augmented by immunotherapy. This report is the first case of the abscopal effect observed in metastatic head-and-neck squamous cell carcinoma (hnscc) treated with concurrent radiotherapy and single-agent nivolumab. Case Description An otherwise healthy 57-year-old man underwent craniofacial resection and adjuvant chemoradiotherapy for advanced sinonasal squamous cell carcinoma. Distant metastatic disease developed shortly after primary treatment, and immunotherapy in the form of nivolumab was initiated. Subsequent oligometastatic progression despite immunotherapy prompted palliative radiotherapy to a single metastasis due to pending symptomatology. Post-radiotherapy, the abscopal effect was observed with all distant sites of metastatic disease shrinking. Five months following treatment, a sustained reduction in disease burden has been demonstrated. Summary We present the first case of the abscopal effect in a patient with metastatic hnscc treated with palliative radiotherapy concurrent with single-agent nivolumab immunotherapy, and only the third case of the abscopal effect in metastatic head-and-neck cancer. Dual treatment with immunotherapy and radiotherapy may be an important treatment option in the future, mediated through the abscopal effect.
Collapse
Affiliation(s)
- D Forner
- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Queen Elizabeth ii Health Sciences Centre and Dalhousie University, Halifax, NS
| | - P Horwich
- Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, U.S.A
| | - J R Trites
- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Queen Elizabeth ii Health Sciences Centre and Dalhousie University, Halifax, NS
| | - H Hollenhorst
- Department of Radiation Oncology, Department of Medicine, Queen Elizabeth ii Health Sciences Centre and Dalhousie University, Halifax, NS
| | - M Bullock
- Department of Pathology, Department of Medicine, Queen Elizabeth ii Health Sciences Centre and Dalhousie University, Halifax, NS
| | - N W D Lamond
- Division of Medical Oncology, Department of Medicine, Queen Elizabeth ii Health Sciences Centre and Dalhousie University, Halifax, NS
| |
Collapse
|
59
|
Farrell NF, Mace JC, Detwiller KY, Li R, Andersen PE, Smith TL, Clayburgh DR, Geltzeiler M. Predictors of survival outcomes in sinonasal squamous cell carcinoma: an analysis of the National Cancer Database. Int Forum Allergy Rhinol 2020; 11:1001-1011. [PMID: 33226198 DOI: 10.1002/alr.22737] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 09/10/2020] [Accepted: 10/02/2020] [Indexed: 01/01/2023]
Abstract
BACKGROUND Sinonasal squamous cell carcinoma (SNSCC) is a rare malignancy that poses management challenges. Although surgery and chemoradiation therapy (CRT) remain therapeutic mainstays, induction chemotherapy (IC) has emerged as a useful adjunct with locally advanced disease. This study used the National Cancer Data Base (NCDB) to examine treatment outcomes for patients diagnosed with SNSCC. METHODS The NCDB (2004-2015) was queried for cases with SNSCC. Multivariate hazard regression modeling was used to identify significant predictors of 24-month and 60-month overall survival (OS) including treatment modality. RESULTS A total of 3516 patients with SNSCC met inclusion criteria, including 1750 patients (49.8%) treated with surgery ± adjuvant therapy, 1352 (38.5%) treated with definitive radiotherapy (RT) or CRT, 300 (8.5%) who underwent IC followed by definitive CRT, and 114 (3.2%) who received IC followed by surgery and adjuvant therapy. Hazard modeling for confirmed treatment modality significantly associated (p < 0.001) with OS after adjustment. Patients who received surgical intervention ± adjuvant therapy had lower 24-month and 60-month mortality risk compared to definitive RT or CRT (hazard ratio [HR] ≥ 1.97; p < 0.001) or IC followed by definitive CRT (HR ≥ 1.73; p < 0.001). Compared to primary surgery ± adjuvant therapy, patients undergoing IC then surgery had similar 24-month and 60-month OS (p ≥ 0.672) after adjustment. CONCLUSION Multimodality therapy, including surgical intervention, associates with improved OS after multifactorial adjustments. IC followed by surgery associated with improved OS compared to IC, followed by CRT and CRT alone. Study results highlight the utility of surgery toward optimizing OS in patients with SNSCC and demonstrates the potential utility of IC when primary surgical management is not preferred.
Collapse
Affiliation(s)
- Nyssa Fox Farrell
- Department of Otolaryngology-Head and Neck Surgery, Division of Rhinology and Sinus Surgery, Oregon Health and Science University, Portland, OR
| | - Jess C Mace
- Department of Otolaryngology-Head and Neck Surgery, Division of Rhinology and Sinus Surgery, Oregon Health and Science University, Portland, OR
| | - Kara Y Detwiller
- Department of Otolaryngology-Head and Neck Surgery, Division of Rhinology and Sinus Surgery, Oregon Health and Science University, Portland, OR.,Portland Veterans Affairs Health Care System, Portland, OR
| | - Ryan Li
- Department of Otolaryngology-Head and Neck Surgery, Division of Head and Neck Surgery, Oregon Health and Science University, Portland, OR
| | - Peter E Andersen
- Department of Otolaryngology-Head and Neck Surgery, Division of Head and Neck Surgery, Oregon Health and Science University, Portland, OR
| | - Timothy L Smith
- Department of Otolaryngology-Head and Neck Surgery, Division of Rhinology and Sinus Surgery, Oregon Health and Science University, Portland, OR
| | - Daniel R Clayburgh
- Portland Veterans Affairs Health Care System, Portland, OR.,Department of Otolaryngology-Head and Neck Surgery, Division of Head and Neck Surgery, Oregon Health and Science University, Portland, OR
| | - Mathew Geltzeiler
- Department of Otolaryngology-Head and Neck Surgery, Division of Rhinology and Sinus Surgery, Oregon Health and Science University, Portland, OR
| |
Collapse
|
60
|
Ting DSJ, Rana-Rahman R, Ng JY, Wilkinson DJP, Ah-Kine D, Patel T. Clinical Spectrum and Outcomes of Ocular and Periocular Complications following External-Beam Radiotherapy for Inoperable Malignant Maxillary Sinus Tumors. Ocul Oncol Pathol 2020; 7:36-43. [PMID: 33796515 DOI: 10.1159/000511011] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 08/19/2020] [Indexed: 12/15/2022] Open
Abstract
Purpose To highlight the clinical spectrum, management, and outcomes of ocular/periocular complications following high-dose external-beam radiotherapy (EBRT) for inoperable malignant maxillary sinus-involving tumors (MMST). Methods A retrospective, interventional case series. All patients who were diagnosed with inoperable MMST (with orbital involvement) and treated with high-dose fractionated EBRT (65 Gy in 30 fractions) at James Cook University Hospital, UK, were included. Results Seven patients with advanced MMST (T4aN0M0-T4bN2cM0) were included and were followed up for 23.8 ± 10.2 months. Severe lid margin disease, dry eye, and neurotrophic keratopathy were universally observed. Other complications included cicatricial conjunctivitis (71%), corneal perforation (57%), limbal stem cell deficiency (LSCD; 43%), glaucoma (29%), and superimposed candida keratitis (14%). Amniotic membrane transplant (AMT; 71%), tarsorrhaphy (43%), tectonic keratoplasty (29%), and evisceration (14%) were warranted. Intact corneal epithelium was observed in all patients and good corrected-distance visual acuity (≥20/60) was observed in 3 (43%) patients at final follow-up. Conclusion High-dose EBRT for inoperable MMST can lead to a wide array of severe ocular/periocular complications. AMT serves as a potentially useful treatment modality to restore the ocular surface integrity after severe radiation keratopathy. We advocate active monitoring for any evolving ophthalmic complications during and after EBRT to enable timely intervention.
Collapse
Affiliation(s)
- Darren Shu Jeng Ting
- Academic Ophthalmology, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom.,Department of Ophthalmology, James Cook University Hospital, Middlesbrough, United Kingdom
| | - Romeela Rana-Rahman
- Department of Ophthalmology, James Cook University Hospital, Middlesbrough, United Kingdom
| | - Jia Yu Ng
- Department of Ophthalmology, James Cook University Hospital, Middlesbrough, United Kingdom
| | - David J P Wilkinson
- Department of Radiotherapy and Oncology, James Cook University Hospital, Middlesbrough, United Kingdom
| | - Desiree Ah-Kine
- Department of Ophthalmology, James Cook University Hospital, Middlesbrough, United Kingdom
| | - Trushar Patel
- Department of Ophthalmology, James Cook University Hospital, Middlesbrough, United Kingdom
| |
Collapse
|
61
|
Meng Z, Zhu S, Liu N, Tian J. miR-362-3p suppresses sinonasal squamous cell carcinoma progression via directly targeting pituitary tumor-transforming gene 1. J Recept Signal Transduct Res 2020; 42:43-51. [PMID: 33148101 DOI: 10.1080/10799893.2020.1839766] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Sinonasal squamous cell carcinoma (SNSCC) is a main subtype of sinonasal malignancy with unclear pathogenesis. microRNAs (miRNAs) are involved in SNSCC progression. Nevertheless, the role and mechanism of miR-362-3p in SNSCC development are unclear. METHODS The SNSCC tissues (n = 23) and normal sinonasal samples (n = 13) were harvested. SNSCC cell line RPMI-2650 cells were transfected using Lipofectamine 3000. miR-362-3p and pituitary tumor-transforming gene 1 (PTTG1) were determined by quantitative reverse transcription polymerase chain reaction and western blot. Cell proliferation was analyzed via Cell Counting Kit-8 and 5-ethynyl-2'-deoxyuridine assays. Cell migration and invasion was assessed using wound healing assay and transwell assay. Epithelial-mesenchymal transition (EMT)-associated protein (E-cadherin, N-cadherin and Vimentin) levels were measured via western blot. The binding relationship was analyzed via bioinformatic analysis and dual-luciferase reporter assay. RESULTS miR-362-3p abundance was decreased in SNSCC samples. miR-362-3p addition constrained cell proliferation, migration, invasion and EMT, but miR-362-3p knockdown played an opposite effect. PTTG1 was targeted and negatively modulated by miR-362-3p. PTTG1 abundance was elevated in SNSCC samples. PTTG1 overexpression mitigated miR-362-3p-modulated suppression of cell proliferation, migration, invasion and EMT in SNSCC cells. CONCLUSION miR-362-3p repressed cell proliferation, migration, invasion and EMT in SNSCC via targeting PTTG1.
Collapse
Affiliation(s)
- Zhaolun Meng
- Department of E. N. T, Qingdao Jiaozhou Center Hospital, Qingdao, Shandong, China
| | - Shu Zhu
- Department of E. N. T, Qingdao Jiaozhou Center Hospital, Qingdao, Shandong, China
| | - Na Liu
- Department of E. N. T, Qingdao Jiaozhou Center Hospital, Qingdao, Shandong, China
| | - Jie Tian
- Department of Otolaryngology, Zibo Center Hospital, Zibo, Shandong, China
| |
Collapse
|
62
|
Azzam P, Mroueh M, Francis M, Daher AA, Zeidan YH. Radiation-induced neuropathies in head and neck cancer: prevention and treatment modalities. Ecancermedicalscience 2020; 14:1133. [PMID: 33281925 PMCID: PMC7685771 DOI: 10.3332/ecancer.2020.1133] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Indexed: 12/24/2022] Open
Abstract
Head and neck cancer (HNC) is the sixth most common human malignancy with a global incidence of 650,000 cases per year. Radiotherapy (RT) is commonly used as an effective therapy to treat tumours as a definitive or adjuvant treatment. Despite the substantial advances in RT contouring and dosage delivery, patients suffer from various radiation-induced complications, among which are toxicities to the nervous tissues in the head and neck area. Radiation-mediated neuropathies manifest as a result of increased oxidative stress-mediated apoptosis, neuroinflammation and altered cellular function in the nervous tissues. Eventually, molecular damage results in the formation of fibrotic tissues leading to susceptible loss of function of numerous neuronal substructures. Neuropathic sequelae following irradiation in the head and neck area include sensorineural hearing loss, alterations in taste and smell functions along with brachial plexopathy, and cranial nerves palsies. Numerous management options are available to relieve radiation-associated neurotoxicities notwithstanding treatment alternatives that remain restricted with limited benefits. In the scope of this review, we discuss the use of variable management and therapeutic modalities to palliate common radiation-induced neuropathies in head and neck cancers.
Collapse
Affiliation(s)
- Patrick Azzam
- Department of Anatomy, Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon
| | - Manal Mroueh
- Department of Anatomy, Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon
| | - Marina Francis
- Department of Anatomy, Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon
| | - Alaa Abou Daher
- Department of Anatomy, Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon
| | - Youssef H Zeidan
- Department of Anatomy, Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon
- Department of Radiation Oncology, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon
| |
Collapse
|
63
|
Hu C, Wang H, Lin L, Sun X, Wang D. Association between carbonic anhydrase 9 expression and poor prognosis in sinonasal squamous cell carcinoma. Ann Diagn Pathol 2020; 49:151643. [PMID: 33126151 DOI: 10.1016/j.anndiagpath.2020.151643] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2020] [Accepted: 10/09/2020] [Indexed: 01/16/2023]
Abstract
OBJECTIVES Carbonic anhydrase 9 (CA9), as a member of the carbonic anhydrase enzyme family, was an endogenous marker of hypoxia. Previous studies suggested CA9 expression was correlated with poor prognosis in multiple types of malignancies. Therefore, this study was to evaluate the role of CA9 in sinonasal squamous cell carcinoma (SNSCC) and to determine whether this biomarker was associated with patient clinicopathologic characteristics and prognosis. METHODS We assessed 63 patients diagnosed with SNSCC in 2013-2017 who underwent curative surgery. Tumor specimens was immunohistochemically analyzed for CA9 expression. The expression levels of CA9 was evaluated in relation to clinicopathological factors and prognosis. RESULTS Positive expression of CA9 was observed in 21 (33.3%) patients and was significantly correlated with local recurrence (p = 0.016), overall survival (OS) (p = 0.003) and disease-free survival (DFS) (p = 0.002). In Cox's multivariate analysis, CA9 expression was an independent negative prognostic factor for OS (p = 0.048) and DFS (p = 0.019). CONCLUSIONS Our findings demonstrated that CA9 overexpression could be used as an independent prognostic biomarker and therapeutic target in SNSCC.
Collapse
Affiliation(s)
- Chunyan Hu
- Department of Clinical Pathology, Eye & ENT Hospital, Fudan University, Shanghai, China
| | - Huan Wang
- Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China
| | - Lan Lin
- Department of Clinical Pathology, Eye & ENT Hospital, Fudan University, Shanghai, China.
| | - Xicai Sun
- Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
| | - Dehui Wang
- Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China
| |
Collapse
|
64
|
Crawford KL, Jafari A, Qualliotine JR, Stuart E, DeConde AS, Califano JA, Orosco RK. Elective neck dissection for T3/T4 cN0 sinonasal squamous cell carcinoma. Head Neck 2020; 42:3655-3662. [PMID: 32830895 DOI: 10.1002/hed.26418] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 06/03/2020] [Accepted: 08/03/2020] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND In locally advanced sinonasal squamous cell carcinoma (SNSCC), management of the clinically node-negative (cN0) neck is variable and elective neck dissection (END) remains controversial. METHODS Patients with surgically treated T3/T4 cN0 M0 SNSCC were identified using the NCDB. Overall survival (OS) was assessed by Cox proportional hazard analysis in propensity score-matched cohorts. Factors associated with END were evaluated with logistic regression. RESULTS Two hundred twenty patients underwent END (19.6%). END did not correlated with OS in propensity score-matched cohorts (HR 0.971, 95% CI 0.677-1.392), a maxillary sinus tumor subgroup (HR 1.089, 95% CI 0.742-1.599), or by radiation status [radiation: (HR 0.802, 95% CI 0.584-1.102); no radiation: (HR 0.852, 95% CI 0.502-1.445)]. The occult metastasis rate in the END cohort was 12.7%. CONCLUSION END did not significantly improve OS in this study. Further information on disease-free survival is necessary to determine its role in advanced-stage SNSCC.
Collapse
Affiliation(s)
- Kayva L Crawford
- Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of California San Diego, San Diego, California, USA
| | - Aria Jafari
- Department of Otolaryngology-Head & Neck Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.,Department of Otolaryngology-Head & Neck Surgery, Harvard Medical School, Boston, Massachusetts, USA
| | - Jesse R Qualliotine
- Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of California San Diego, San Diego, California, USA
| | - Emelia Stuart
- School of Medicine, University of California San Diego, San Diego, California, USA
| | - Adam S DeConde
- Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of California San Diego, San Diego, California, USA
| | - Joseph A Califano
- Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of California San Diego, San Diego, California, USA.,Moores Cancer Center, La Jolla, California, USA
| | - Ryan K Orosco
- Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of California San Diego, San Diego, California, USA.,Moores Cancer Center, La Jolla, California, USA
| |
Collapse
|
65
|
Li Y, Wang C, Wang R, Zhang J, Liu H, Shi Q, Chen X, Hou L, Ma H, Zhong Q, Li P, Feng L, He S, Zhang L, Fang J. Prognostic Factors of Sinonasal Squamous Cell Carcinomas Arising De Novo and From Inverted Papilloma. Am J Rhinol Allergy 2020; 35:114-121. [PMID: 32659112 DOI: 10.1177/1945892420939422] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND The prognostic factors and survival difference between inverted papilloma (IP)-associated sinonasal squamous cell carcinoma (SCC) and de novo SCC are unclear. OBJECTIVE This study aimed to compare the clinical features and oncologic outcomes in patients with IP-associated SCC and de novo SCC; and additionally, to analyze the prognostic factors of the two types of SCCs. METHODS Data from 173 SCC patients treated for IP-associated SCC (n = 89) and de novo SCC (n = 84), were reviewed retrospectively for demographic features, tumor characteristics, treatment modality, and clinical outcomes. 5-year overall survival (OS) and disease free survival (DFS) was analyzed using the Kaplan-Meier method, and Cox proportional hazards model was used to analyze factors influencing prognosis. RESULTS A higher proportion of IP-associated SCC occurred in frontal and sphenoid sinus compared to de novo SCC. The two groups demonstrated similar 5-year OS and DFS (5-year OS: 63.3% and 55.4%, DFS: 45.4% and 50.1%, respectively). The metachronous tumor had a relatively better prognosis outcome than synchronous tumor and de novo SCC (5-year OS: 73.1%, 54.5% and 55.4%, respectively). Both groups showed similar loco-regional recurrence rates (p > 0.05); however, de novo SCC tumors demonstrated an increased incidence of distant metastasis. Multivariate analysis indicated that age >70 years, advanced tumor stage and surgical margin were independent predictive factors for the risk of mortality (HR 2.047, 1.581 and 1.931, respectively). CONCLUSION IP-associated SCCs have an aggressive loco-regional tendency, whereas de novo SCCs have a higher aggressive distant metastatic propensity. Age, tumor stage and surgical positive margin are key factors for poor prognosis and should be routinely taken into consideration during treatment planning and subsequent surveillance.
Collapse
Affiliation(s)
- Yunxia Li
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China
| | - Chengshuo Wang
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Ru Wang
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Jiamin Zhang
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China
| | - Honggang Liu
- Department of Pathology, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Head and Neck Molecular Diagnostic Pathology, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China
| | - Qian Shi
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Xiaohong Chen
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Lizhen Hou
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Hongzhi Ma
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Qi Zhong
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Pingdong Li
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Ling Feng
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Shizhi He
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Luo Zhang
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Jugao Fang
- Department of Otolaryngology Head and Neck Surgery, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Beijing, PR China.,Key Laboratory of Head and Neck Molecular Diagnostic Pathology, 117902Beijing Tongren Hospital, Capital Medical University, Beijing, PR China
| |
Collapse
|
66
|
Teitelbaum JI, Issa K, Barak IR, Ackall FY, Jung SH, Jang DW, Abi Hachem R. Sinonasal Squamous Cell Carcinoma Outcomes: Does Treatment at a High-Volume Center Confer Survival Benefit? Otolaryngol Head Neck Surg 2020; 163:986-991. [DOI: 10.1177/0194599820935395] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Objective To determine whether treatment of sinonasal squamous cell carcinoma (SCC) at a high-volume facility affects survival. Study Design Retrospective database analysis. Setting National Cancer Database (2004-2014). Subjects and Methods The National Cancer Database was queried for sinonasal SCC from 2004 to 2014. Patient demographics, tumor characteristics and classification, resection margins, treatment regimen, and facility case-specific volume—averaged per year and grouped in tertiles as low (0%-33%), medium (34%-66%), and high (67%-100%)—were compared. Overall survival was compared with Cox proportional hazards regression analysis. Results A total of 3835 patients treated for sinonasal SCC between 2004 and 2014 were identified. Therapeutic options included surgery alone (18.6%), radiotherapy (RT) alone (29.1%), definitive chemoradiation (15.4%), surgery with adjuvant RT (22.8%), and combinations (14.1%) of the aforementioned treatments. Patients who underwent surgery with adjuvant RT had better overall survival (hazard ratio [HR], 0.74; P < .001; 95% CI, 0.63-0.86). As for treatment volume per facility, 7.4% of patients were treated at a low-volume center, 17.5% at a medium-volume center, and 75.1% at a high-volume center. Univariate analysis showed that treatment at a high-volume facility conferred a significantly better overall survival (HR, 0.77; P = .002). Multivariable Cox proportional hazards regression analysis, adjusting for age, sex, tumor classification, and treatment regimen, demonstrated that patients who underwent treatment at a high-volume facility (HR, 0.81; P < .001) had significantly improved survival. Conclusion This study shows a better overall survival for sinonasal SCC treated at high-volume centers. Further study may be needed to understand the effect of case volume on the paradigms of sinonasal SCC management.
Collapse
Affiliation(s)
- Jordan I. Teitelbaum
- Division of Rhinology and Skull Base Surgery, Department of Head and Neck Surgery and Communication Sciences, Duke University Health System, Durham, North Carolina, USA
| | - Khalil Issa
- Division of Rhinology and Skull Base Surgery, Department of Head and Neck Surgery and Communication Sciences, Duke University Health System, Durham, North Carolina, USA
| | - Ian R. Barak
- Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA
| | - Feras Y. Ackall
- Division of Rhinology and Skull Base Surgery, Department of Head and Neck Surgery and Communication Sciences, Duke University Health System, Durham, North Carolina, USA
| | - Sin-Ho Jung
- Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA
| | - David W. Jang
- Division of Rhinology and Skull Base Surgery, Department of Head and Neck Surgery and Communication Sciences, Duke University Health System, Durham, North Carolina, USA
| | - Ralph Abi Hachem
- Division of Rhinology and Skull Base Surgery, Department of Head and Neck Surgery and Communication Sciences, Duke University Health System, Durham, North Carolina, USA
| |
Collapse
|
67
|
AKKAŞ AKGÜN G, ASLAN F. Kliniğimizde tanı almış sinonazal bölge lezyonlarının retrospektif olarak değerlendirilmesi. EGE TIP DERGISI 2020. [DOI: 10.19161/etd.756306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
68
|
Lee HY, Lee HK, Kim SJ. Squamous Cell Carcinoma In Situ Originating From Nasal Polyps With Human Papillomavirus 51 Infection: A Case Report. EAR, NOSE & THROAT JOURNAL 2020; 100:1054S-1057S. [PMID: 32579382 DOI: 10.1177/0145561320933393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Malignant transformation of nasal polyps is extremely rare in cases without background inverted papilloma. Human papillomavirus (HPV) is a sexually transmitted infection believed to be associated with oropharyngeal carcinoma via oro-genital sexual contact. We present a case of focal squamous cell carcinoma in situ that occurred on the surface of nasal polyps and was associated with HPV 51. The patient was successfully treated with endoscopic sinus surgery. Clinicians should be aware of the potential for hidden malignancies, and pathologic assessment of tissue specimens must be performed even in simple nasal polyp cases.
Collapse
Affiliation(s)
- Ho Yun Lee
- Department of Otorhinolaryngology - Head and Neck Surgery, College of Medicine, Ewha Womans University, Seoul, Republic of Korea
| | - Hye Kyung Lee
- Department of Pathology, Eulji University School of Medicine, Daejeon, Republic of Korea
| | - Su Jin Kim
- Department of Otorhinolaryngology - Head and Neck Surgery, Eulji University School of Medicine, Daejeon, Republic of Korea
| |
Collapse
|
69
|
Wang H, Hu C, Song X, Hu L, Li W, Yu H, Sun X, Wang D. Expression of Podoplanin in Sinonasal Squamous Cell Carcinoma and Its Clinical Significance. Am J Rhinol Allergy 2020; 34:800-809. [PMID: 32551858 DOI: 10.1177/1945892420930976] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND It was recently suggested that the upregulation of podoplanin (PDPN) in cancer cells plays a significant role in tumor invasion and metastasis and that it is significantly associated with poor prognosis in oral, cutaneous, and esophageal squamous cell carcinoma. The aim of this study was to investigate the expression pattern of PDPN in sinonasal squamous cell carcinoma (SNSCC) and to evaluate its role as a prognostic factor for survival outcome. PATIENTS AND METHODS This study included 59 subjects with SNSCC. We retrospectively collected the clinical features of these patients from medical records and retrieved the associated formalin-fixed, paraffin-embedded tissues for PDPN immunohistochemical staining. Furthermore, PDPN expression was analyzed in relation to the patients' clinicopathological features and prognosis. RESULTS We observed positive staining for PDPN in both cancer cells and stromal cancer-associated fibroblasts (CAFs). Positive expression of PDPN in cancer cells of patients with SNSCC was significantly correlated with the primary tumor site (p = 0.009) and local recurrence (p = 0.024). In addition, patients with PDPN-positive cancer cells had significantly lower overall survival (OS) and disease-free survival (DFS) rates than did patients with PDPN-negative cancer cells (both p < 0.05). Multivariate analysis revealed that PDPN expression in cancer cells was an independent prognostic factor for both OS (p = 0.038) and DFS (p = 0.039). CONCLUSIONS Our findings demonstrated that PDPN overexpression may be both an independent prognostic biomarker and a therapeutic target in SNSCC.
Collapse
Affiliation(s)
- Huan Wang
- Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, China
| | - Chunyan Hu
- Department of Clinical Pathology, Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, China
| | - Xiaole Song
- Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, China
| | - Li Hu
- Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, China.,Department of Clinical Laboratory, Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, China
| | - Wanpeng Li
- Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, China
| | - Hongmeng Yu
- Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, China
| | - Xicai Sun
- Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, China
| | - Dehui Wang
- Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, China
| |
Collapse
|
70
|
Al-Qurayshi Z, Smith R, Walsh JE. Sinonasal Squamous Cell Carcinoma Presentation and Outcome: A National Perspective. Ann Otol Rhinol Laryngol 2020; 129:1049-1055. [PMID: 32476435 DOI: 10.1177/0003489420929048] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND examine presentation and outcomes of sinonasal squamous cell carcinoma (SCC). METHODS A retrospective study utilizing the National Cancer Database, 2004 to 2015. The study population included adult patients diagnosed with primary sinonasal SCC. RESULTS A total of 537 patients were included. The mean age of the study population was 62.6 ± 12.7 years. The median follow-up time was 35.6 months (interquartile range: 8.6-55.9). The histological variants identified are: (i) 66.7% keratinizing SCC, (ii) 21.6% non-keratinizing SCC, (iii) 8.0% papillary SCC, and (iv) 3.7% spindle cell carcinoma. Stage at presentation was: (i) 33.3% T1-2, N0, (ii) 31.8% T3-4a, N0, (iii) 13.8% T1-4a, N+, (iv) 17.0% T4b,N0-3, (v) 4.1% M1. Human papilloma virus (HPV) status was available for 96 patients and tested positive in 24 (25.0%) patients. By histological variants, 5-year survival was lowest for spindle cell carcinoma (40.0%), and highest for papillary SCC (70.1%). HPV negative tumors had a 5-year survival of 26.4%, while HPV positive tumors had a 5-year survival of 57.1% (P = <.001). Of the 255 patients with T1-4a, N0-3, M0 who had surgery of the primary site, 31 (12.2%) patients underwent endoscopic approach. The risk of positive postsurgical margins was not significantly different comparing endoscopic to open approach (23.8% vs 24.1%, P >.99). CONCLUSIONS Sinonasal SCC could present at advanced stages in two-thirds of the population and exhibit a variety of histological subtypes. Like other sites of head and neck, HPV positive tumors are associated with a favorable prognosis. Endoscopic approach is comparable to open approach in terms of post-surgical margins.
Collapse
Affiliation(s)
- Zaid Al-Qurayshi
- Department of Otolaryngology - Head & Neck Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - Ryan Smith
- Department of Otolaryngology - Head & Neck Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - Jarrett E Walsh
- Department of Otolaryngology - Head & Neck Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| |
Collapse
|
71
|
Wang EW, Zanation AM, Gardner PA, Schwartz TH, Eloy JA, Adappa ND, Bettag M, Bleier BS, Cappabianca P, Carrau RL, Casiano RR, Cavallo LM, Ebert CS, El-Sayed IH, Evans JJ, Fernandez-Miranda JC, Folbe AJ, Froelich S, Gentili F, Harvey RJ, Hwang PH, Jane JA, Kelly DF, Kennedy D, Knosp E, Lal D, Lee JYK, Liu JK, Lund VJ, Palmer JN, Prevedello DM, Schlosser RJ, Sindwani R, Solares CA, Tabaee A, Teo C, Thirumala PD, Thorp BD, de Arnaldo Silva Vellutini E, Witterick I, Woodworth BA, Wormald PJ, Snyderman CH. ICAR: endoscopic skull-base surgery. Int Forum Allergy Rhinol 2020; 9:S145-S365. [PMID: 31329374 DOI: 10.1002/alr.22326] [Citation(s) in RCA: 80] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2018] [Revised: 02/12/2019] [Accepted: 02/15/2019] [Indexed: 12/30/2022]
Abstract
BACKGROUND Endoscopic skull-base surgery (ESBS) is employed in the management of diverse skull-base pathologies. Paralleling the increased utilization of ESBS, the literature in this field has expanded rapidly. However, the rarity of these diseases, the inherent challenges of surgical studies, and the continued learning curve in ESBS have resulted in significant variability in the quality of the literature. To consolidate and critically appraise the available literature, experts in skull-base surgery have produced the International Consensus Statement on Endoscopic Skull-Base Surgery (ICAR:ESBS). METHODS Using previously described methodology, topics spanning the breadth of ESBS were identified and assigned a literature review, evidence-based review or evidence-based review with recommendations format. Subsequently, each topic was written and then reviewed by skull-base surgeons in both neurosurgery and otolaryngology. Following this iterative review process, the ICAR:ESBS document was synthesized and reviewed by all authors for consensus. RESULTS The ICAR:ESBS document addresses the role of ESBS in primary cerebrospinal fluid (CSF) rhinorrhea, intradural tumors, benign skull-base and orbital pathology, sinonasal malignancies, and clival lesions. Additionally, specific challenges in ESBS including endoscopic reconstruction and complication management were evaluated. CONCLUSION A critical review of the literature in ESBS demonstrates at least the equivalency of ESBS with alternative approaches in pathologies such as CSF rhinorrhea and pituitary adenoma as well as improved reconstructive techniques in reducing CSF leaks. Evidence-based recommendations are limited in other pathologies and these significant knowledge gaps call upon the skull-base community to embrace these opportunities and collaboratively address these shortcomings.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Adam J Folbe
- Michigan Sinus and Skull Base Institute, Royal Oak, MI
| | | | | | - Richard J Harvey
- University of Toronto, Toronto, Canada.,University of New South Wales, Sydney, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Charles Teo
- Prince of Wales Hospital, Randwick, Australia
| | | | | | | | | | | | | | | |
Collapse
|
72
|
Park JC, Faquin WC, Durbeck J, Faden DL. Immune checkpoint inhibitors in sinonasal squamous cell carcinoma. Oral Oncol 2020; 109:104776. [PMID: 32414645 DOI: 10.1016/j.oraloncology.2020.104776] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Accepted: 05/04/2020] [Indexed: 02/03/2023]
Affiliation(s)
| | | | | | - Daniel L Faden
- Massachusetts Eye and Ear, Boston, MA, USA; Massachusetts General Hospital, USA; Harvard Medical School, USA.
| |
Collapse
|
73
|
Ranasinghe VJ, Stubbs VC, Reny DC, Fathy R, Brant JA, Newman JG. Predictors of nodal metastasis in sinonasal squamous cell carcinoma: A national cancer database analysis. World J Otorhinolaryngol Head Neck Surg 2020; 6:137-141. [PMID: 32596660 PMCID: PMC7296471 DOI: 10.1016/j.wjorl.2020.01.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Accepted: 01/19/2020] [Indexed: 02/03/2023] Open
Abstract
Objective We present the largest population based study of sinonasal squamous cell carcinoma (SCC) to identify risk factors for presentation with nodal metastasis. Methods The National Cancer Database (NCDB) was used for this study. Location codes corresponding to the nasal cavity and paranasal sinuses and histology codes representing SCC malignancy were queried. Logistic regression analysis was performed to identify factors associated with presentation with nodal metastasis. Results 6448 cases met inclusion criteria. Nodal metastasis at presentation was seen in 13.2% of patients, with the sinus subsite (19.3%) being a significant risk factor for nodal metastasis at presentation when compared to the nasal cavity (7.9%). Logistic regression analysis showed black, uninsured and Medicaid patients were more likely than white and privately insured patients, respectively, to present with nodal metastasis. Conclusions In sinonasal SCC, the sinus subsite has a significantly increased risk of nodal metastasis compared to the nasal cavity. Black race, uninsured and Medicaid patients are more likely to have nodal metastasis at presentation.
Collapse
Affiliation(s)
- Viran J Ranasinghe
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States
| | - Vanessa C Stubbs
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States
| | - Danielle C Reny
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Ramie Fathy
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Jason A Brant
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States
| | - Jason G Newman
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States
| |
Collapse
|
74
|
Yu B, Qu L, Wu T, Yan B, Kan X, Zhao X, Yang L, Li Y, Liu M, Tian L, Sun Y, Li Q. A Novel LncRNA, AC091729.7 Promotes Sinonasal Squamous Cell Carcinomas Proliferation and Invasion Through Binding SRSF2. Front Oncol 2020; 9:1575. [PMID: 32039035 PMCID: PMC6992602 DOI: 10.3389/fonc.2019.01575] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2019] [Accepted: 12/31/2019] [Indexed: 01/31/2023] Open
Abstract
Long non-coding RNAs (lncRNAs) play important roles in various biological progresses of carcinogenesis. However, the function of lncRNAs in human sinonasal squamous cell carcinoma (SNSCC) remains greatly unclear. In the current study, lncRNA AC091729.7 expression was examined in SNSCC samples by using microarray, RNA in situ hybridization (ISH) and real-time fluorescence quantitative PCR (qRT-PCR). Cell viability, colony-formation, wound-healing, and transwell assays were applied to SNSCC cells. Xenograft mouse models were employed to evaluate the role of AC091729.7 in growth of SNSCC in vivo. Human protein microarray (HuprotTM Protoarray) and RNA immunoprecipitation (RIP) were used for identifying AC091729.7 binding proteins in SNSCC. Results showed AC091729.7 was upregulated and closely connected with the survival of the SNSCC patients. Knockdown of AC091729.7 suppressed SNSCC cell migration, proliferation, invasion in vitro. Furthermore, downregulation of AC091729.7 could inhibit the growth of SNSCC in vivo. Moreover, Human protein microarray and RIP suggested that AC091729.7 directly combine with the serine/arginine rich splicing factor 2 (SRSF2). Our results suggest that in the cell progression of SNSCC, lncRNA AC091729.7 plays a carcinogenic role and serves as a novel biomarker and latent curative target in SNSCC patients.
Collapse
Affiliation(s)
- Boyu Yu
- Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Linmei Qu
- Department of Otorhinolaryngology, Head and Neck Surgery, The Fifth Affiliated Hospital, Harbin Medical University, Daqing, China
| | - Tianyi Wu
- Department of Otorhinolaryngology, Head and Neck Surgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China
| | - Bingrui Yan
- Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Xuan Kan
- Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Xuehui Zhao
- Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Like Yang
- Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Yushan Li
- Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Ming Liu
- Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Linli Tian
- Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Yanan Sun
- Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Qiuying Li
- Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
| |
Collapse
|
75
|
Mody MD, Saba NF. Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment. Curr Treat Options Oncol 2020; 21:4. [PMID: 31950286 DOI: 10.1007/s11864-019-0696-4] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
OPINION STATEMENT Sinonasal malignancies pose a significant challenge in management due to their low incidence, biologic diversity, and significant symptom burden. Even though surgery remains the primary therapeutic modality, a multi-modality approach has been shown to benefit a significant proportion of patients and its success depends largely on stage and histologic type. Non-surgical approaches such as novel radiation approaches as well as intensification with systemic therapy hold promise in altering the organ preservation rate as well as overall survival for patients. Practice changing randomized trials to test these novel modalities are overdue and desperately needed.
Collapse
Affiliation(s)
- Mayur D Mody
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.,Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - Nabil F Saba
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA. .,Winship Cancer Institute of Emory University, Atlanta, GA, USA.
| |
Collapse
|
76
|
Torabi SJ, Spock T, Cardoso B, Chao J, Morse E, Manes RP, Judson BL. Margins in Sinonasal Squamous Cell Carcinoma: Predictors, Outcomes, and the Endoscopic Approach. Laryngoscope 2019; 130:E388-E396. [PMID: 31755988 DOI: 10.1002/lary.28315] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Revised: 08/14/2019] [Accepted: 09/03/2019] [Indexed: 01/28/2023]
Abstract
OBJECTIVES To identify factors associated with positive margins following surgical management of sinonasal squamous cell carcinoma (SNSCC), especially with regard to endoscopic treatment. METHODS In a retrospective analysis of adult patients with clinically staged tumor (T)1 to T4a SNSCC within the National Cancer Database (NCDB) from 2004 to 2014, factors were associated with positive margins using multivariable binary logistic regression. Cases from 2010 to 2014 had surgical approach (open vs. endoscopic) available and were analyzed in a subgroup to assess the association of surgical approach with margin status. The association of margin status with overall survival (OS) and additional therapy administration was also assessed. RESULTS We identified 2,968 cases, of which 807 (27.2%) had positive margins. On multivariable analysis, factors associated with positive margins included higher T stage (T4a vs. T1: odds ratio [OR] 2.768 [95% CI 2.143-3.577]), less differentiated tumors (poorly differentiated vs. well differentiated: OR 1.403 [95% CI 1.060-1.856]), and tumors in the ethmoid sinus (vs. nasal cavity; OR 1.889 [95% CI 1.305-2.734]). Cases treated at higher volume facilities (HVFs) were associated with a lower likelihood of positive margins (OR 0.716 [95% CI 0.582-0.881]). Positive margins were associated with decreased OS (hazard ratio 1.672 [95% CI 1.464-1.908]) and an increased rate of additional therapy (OR 1.966 [95% confidence interval 1.597-2.421]). An endoscopic approach was not associated with an increased likelihood of obtaining positive margins (vs. open; OR 1.151 [0.903-1.651]). CONCLUSION Positive margins were less likely when performed at HVFs and more likely in the ethmoid sinus than other subsites. Importantly, there was no association between positive margins and surgical approach. Endoscopic surgery may offer a safe, less invasive alternative to open surgery for select patients. LEVEL OF EVIDENCE NA Laryngoscope, 130:E388-E396, 2020.
Collapse
Affiliation(s)
- Sina J Torabi
- Department of Surgery (Division of Otolaryngology), Yale University School of Medicine, New Haven, Connecticut
| | - Todd Spock
- Department of Otolaryngology, Mount Sinai Health, New York, New York, U.S.A
| | - Bruno Cardoso
- Department of Surgery (Division of Otolaryngology), Yale University School of Medicine, New Haven, Connecticut
| | - Janet Chao
- Department of Surgery (Division of Otolaryngology), Yale University School of Medicine, New Haven, Connecticut
| | - Elliot Morse
- Department of Otolaryngology, New York Presbyterian Hospital-Columbia and Cornell, New York, New York, U.S.A
| | - R Peter Manes
- Department of Surgery (Division of Otolaryngology), Yale University School of Medicine, New Haven, Connecticut
| | - Benjamin L Judson
- Department of Surgery (Division of Otolaryngology), Yale University School of Medicine, New Haven, Connecticut.,Yale Cancer Center, New Haven, Connecticut
| |
Collapse
|
77
|
Weindorf SC, Brown NA, McHugh JB, Udager AM. Sinonasal Papillomas and Carcinomas: A Contemporary Update With Review of an Emerging Molecular Classification. Arch Pathol Lab Med 2019; 143:1304-1316. [DOI: 10.5858/arpa.2019-0372-ra] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Context.—
Sinonasal papillomas and carcinomas are uncommon head and neck neoplasms that comprise a broad clinicopathologic and morphologic spectrum, and thus frequently represent a diagnostic challenge for surgical pathologists. Recent molecular interrogation of these tumors has delineated a number of recurrent alterations that correspond to distinct entities with potential diagnostic and/or therapeutic clinical utility.
Objective.—
To summarize the salient clinicopathologic, morphologic, and molecular features of sinonasal papillomas and carcinomas.
Data Sources.—
Review of pertinent literature regarding sinonasal papillomas and sinonasal carcinomas.
Conclusions.—
Despite their relative rarity in many surgical pathology practices, sinonasal papillomas and carcinomas frequently demonstrate characteristic morphologic features that are important for accurate diagnosis. Given our emerging understanding of the molecular basis for these tumors, judicious use of available ancillary tools—including immunohistochemistry and in situ hybridization—may be helpful in subsets of cases, whereas additional molecular testing may be useful for diagnostically challenging and/or clinically aggressive sinonasal tumors.
Collapse
Affiliation(s)
- Steven C. Weindorf
- From the Department of Pathology, University of Michigan Medical School, Ann Arbor (Drs Weindorf, Brown, McHugh, and Udager)
| | - Noah A. Brown
- From the Department of Pathology, University of Michigan Medical School, Ann Arbor (Drs Weindorf, Brown, McHugh, and Udager)
| | - Jonathan B. McHugh
- From the Department of Pathology, University of Michigan Medical School, Ann Arbor (Drs Weindorf, Brown, McHugh, and Udager)
| | - Aaron M. Udager
- From the Department of Pathology, University of Michigan Medical School, Ann Arbor (Drs Weindorf, Brown, McHugh, and Udager)
- the University of Michigan Rogel Cancer Center, Ann Arbor (Dr Udager)
- and the Michigan Center for Translational Pathology, Ann Arbor (Dr Udager)
| |
Collapse
|
78
|
Martínez-Rodríguez N, Barona Dorado C, Cortés-Bretón Brinkmann J, Martín Ares M, Sanz Alonso J, Martínez-González JM. Dental considerations in diagnosis of maxillary sinus carcinoma: A patient series of 24 cases. J Am Dent Assoc 2019; 149:976-982. [PMID: 30724169 DOI: 10.1016/j.adaj.2018.07.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2018] [Revised: 07/01/2018] [Accepted: 07/18/2018] [Indexed: 02/03/2023]
Abstract
BACKGROUND Maxillary sinus carcinoma is a rare entity with an incidence of 0.2% and a low patient survival rate due to the frequency of late diagnosis. METHODS In this multicenter, transversal, retrospective, observational study, the authors analyzed patients who had received a diagnosis of maxillary sinus carcinoma, registering their oral symptoms, histologic type, treatment efficacy, and survival rate. RESULTS Maxillary sinus carcinoma was diagnosed in 24 patients (15 men and 9 women), of which 75% were squamous cell carcinomas. All patients had dental mobility, and some had swelling, orosinus fistula, or some dental loss. Mean patient survival rate was 38.83 months. CONCLUSIONS A history of pain or swelling of unknown origin, an unexplained widening of periodontal ligament space, or mobility of the teeth should be considered warning signs of maxillary sinus carcinoma. PRACTICAL IMPLICATIONS Recognition of oral symptoms by the dentist would help in making an early diagnosis of maxillary sinus carcinoma, improving the patient's chances of survival and quality of life.
Collapse
|
79
|
Hermsen MA, Riobello C, García-Marín R, Cabal VN, Suárez-Fernández L, López F, Llorente JL. Translational genomics of sinonasal cancers. Semin Cancer Biol 2019; 61:101-109. [PMID: 31560943 DOI: 10.1016/j.semcancer.2019.09.016] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Accepted: 09/22/2019] [Indexed: 02/06/2023]
Abstract
The sinonasal cavities harbor a wide variety of histologically distinct cancers, the majority very aggressive with 5-year survival rates between 30-60% and local recurrence as the main cause of death. This is a complex anatomic area, close to structures such the eyes and the brain, which is of special relevance for surgery and postoperative radiotherapy. The low incidence of these rare tumors hampers accumulation of experience with diagnosis and clinical managment as well as knowledge on recurrent genetic aberrations or testing of new treatment strategies. However, recent years have seen a growing number of publications on genetic aberrations providing data that can aid or fine-tune classification and provide molecular targets for treatment with specific inhibitors. In addition, new sinonasal cancer models are created that enable preclinical testing of candidate inhibitor drugs. With more and more novel targeted therapies being developed, options for personalized treatment of sinonasal cancer patients are now opening up.
Collapse
Affiliation(s)
- Mario A Hermsen
- Dept. Head and Neck Oncology, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
| | - Cristina Riobello
- Dept. Head and Neck Oncology, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | - Rocío García-Marín
- Dept. Head and Neck Oncology, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | - Virginia N Cabal
- Dept. Head and Neck Oncology, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | - Laura Suárez-Fernández
- Dept. Head and Neck Oncology, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | - Fernando López
- Dept. Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - José L Llorente
- Dept. Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain
| |
Collapse
|
80
|
Li R, Tian S, Lin L, Liu Q, Wang S. Comparative outcome of surgical and nonsurgical therapy for T4bN0M0 sinonasal squamous cell carcinomas. Eur Arch Otorhinolaryngol 2019; 276:3113-3122. [PMID: 31451900 DOI: 10.1007/s00405-019-05601-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2019] [Accepted: 08/10/2019] [Indexed: 02/03/2023]
Abstract
PURPOSE Definitive radiotherapy (RT) is recommended by NCCN guidelines for T4b tumors of sinonasal squamous cell carcinomas (SNSCC). However, no multi-institutional clinical studies have proved its advantage over surgery-based modalities. The aim of this study was to assess the survival of T4bN0M0 SNSCC patients who received surgery plus postoperative radiation (S + PORT) compared with those who received RT. METHODS This study extracted 220 patients from the SEER database from 2004 to 2015. Propensity score matching (PSM) was used to eliminate the baseline variations. RESULTS In SEER database, 43.6% of patients received S + PORT, and subsequently followed by RT (36.4%). Five-year overall survival (OS) and cancer-specific survival rates (CSS) in S + PORT were 42.5% and 46.9%, respectively, significantly better than for RT (21.7% and 26.7%). Multivariate analysis showed that therapy of RT had higher cancer-specific mortality risk than S + PORT [hazard ratio (HR) 1.578, p = 0.032]. After PSM, 57 pairs of patients were selected. There was still a significant difference noted with regard to 5-year OS or 5-year CSS between patients receiving S + PORT and RT (43% vs 22.5%, p = 0.012; 45.8% vs 27.7%, p = 0.025). The univariate and multivariate analyses of factors predictive of CSS showed that therapy of RT (HR 1.877, p = 0.018) and primary subsite of maxillary sinus (HR 2.629, p = 0.001) were significantly correlated with adverse outcomes. CONCLUSION Combination of surgery and postoperative radiotherapy may contribute to prolonged survival in T4bN0M0 SNSCC. Invasion of the sites of T4b tumors is not an absolute contraindication for surgery.
Collapse
Affiliation(s)
- Ruichen Li
- Department of Radiation Oncology, Eye, Ear, Nose and Throat Hospital of Fudan University, 83 Fenyang Road, Xuhui, Shanghai, 200031, People's Republic of China
| | - Shu Tian
- Department of Radiation Oncology, Eye, Ear, Nose and Throat Hospital of Fudan University, 83 Fenyang Road, Xuhui, Shanghai, 200031, People's Republic of China
| | - Lan Lin
- Department of Pathology, Eye, Ear, Nose and Throat Hospital of Fudan University, Shanghai, 200031, People's Republic of China
| | - Quan Liu
- Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital of Fudan University, Shanghai, 200031, People's Republic of China
| | - Shengzi Wang
- Department of Radiation Oncology, Eye, Ear, Nose and Throat Hospital of Fudan University, 83 Fenyang Road, Xuhui, Shanghai, 200031, People's Republic of China.
| |
Collapse
|
81
|
Desai PB, Bukatko AR, Simpson MC, Adjei Boakye E, Greenberg JW, Ward GM, Walker RJ, Antisdel JL, Osazuwa Peters N. Comorbidity burden and nonclinical factors associated with sinonasal cancer all‐cause mortality. Laryngoscope 2019; 130:1443-1449. [DOI: 10.1002/lary.28223] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Revised: 06/24/2019] [Accepted: 07/19/2019] [Indexed: 12/14/2022]
Affiliation(s)
- Premal B. Desai
- Saint Louis University School of Medicine St. Louis Missouri U.S.A
| | - Aleksandr R. Bukatko
- Department of Otolaryngology–Head and Neck SurgerySaint Louis University School of Medicine St. Louis Missouri U.S.A
| | - Matthew C. Simpson
- Department of Otolaryngology–Head and Neck SurgerySaint Louis University School of Medicine St. Louis Missouri U.S.A
| | - Eric Adjei Boakye
- the Department of Population Science and PolicySouthern Illinois University School of Medicine Springfield Illinois U.S.A
| | | | - Greg M. Ward
- Department of Otolaryngology–Head and Neck SurgerySaint Louis University School of Medicine St. Louis Missouri U.S.A
| | - Ronald J. Walker
- Department of Otolaryngology–Head and Neck SurgerySaint Louis University School of Medicine St. Louis Missouri U.S.A
| | - Jastin L. Antisdel
- Department of Otolaryngology–Head and Neck SurgerySaint Louis University School of Medicine St. Louis Missouri U.S.A
| | - Nosayaba Osazuwa Peters
- Department of Otolaryngology–Head and Neck SurgerySaint Louis University School of Medicine St. Louis Missouri U.S.A
- Saint Louis University Cancer Center St. Louis Missouri U.S.A
| |
Collapse
|
82
|
Li Y, Wang C, Wang R, He S, Feng L, Ma H, Lian M, Shi Q, Zhong Q, Chen X, Fang J, Zhang L. Survival outcomes and prognostic factors of squamous cell carcinomas arising from sinonasal inverted papillomas: a retrospective analysis of 120 patients. Int Forum Allergy Rhinol 2019; 9:1367-1373. [PMID: 31403753 DOI: 10.1002/alr.22400] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2019] [Revised: 06/27/2019] [Accepted: 07/16/2019] [Indexed: 02/03/2023]
Abstract
BACKGROUND This study aimed to analyze the prognostic factors and survival outcomes of squamous cell carcinoma (SCC) originating from sinonasal inverted papillomas (IPs), based on data from a single institution. METHODS The data from 120 patients treated at the affiliated Beijing Tongren Hospital, Capital Medical University, for SCC originating from sinonasal IPs between 2005 and 2018 were retrospectively reviewed. Data related to demographic features, tumor characteristics, treatment modality, and clinical outcomes were collected. Survival data were investigated using the Kaplan-Meier method, Cox regression analysis, and the nomogram model predictive of survival probabilities. RESULTS Among 1034 patients with sinonasal IPs, 120 patients (11.6%) with malignancy were identified. The overall survival (OS) and disease-free survival (DFS) rates at 5 years were 56.0% and 42.3%, respectively. Multivariate analysis showed that synchronous tumors and tumor stage were independent predictive factors for the risk of mortality (hazard ratio [HR], 1.954; 95% confidence interval [CI], 1.022-3.737, p = 0.043; HR, 1.737, 95% CI, 1.095-2.770, p = 0.020, respectively). The surgical margin was another important independent predictor, with patients with negative margins demonstrating a more than 2-fold improved survival compared to those with positive margins (HR, 2.095; 95% CI, 1.031-4.243; p = 0.041). CONCLUSION The main factors affecting the prognosis and outcomes were synchronous tumors, advanced tumor stage, and positive surgical margins. These findings highlight the importance of tumor biology and early detection in patient outcomes. In addition, risk factors should be taken into consideration during treatment planning and subsequent tumor surveillance.
Collapse
Affiliation(s)
- Yunxia Li
- Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China
| | - Chengshuo Wang
- Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology-Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Ru Wang
- Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology-Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Shizhi He
- Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology-Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Ling Feng
- Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology-Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Hongzhi Ma
- Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology-Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Meng Lian
- Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology-Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Qian Shi
- Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology-Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Qi Zhong
- Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology-Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Xiaohong Chen
- Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology-Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Jugao Fang
- Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology-Head and Neck Surgery, Capital Medical University, Beijing, PR China
| | - Luo Zhang
- Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China.,Key Laboratory of Otolaryngology-Head and Neck Surgery, Capital Medical University, Beijing, PR China
| |
Collapse
|
83
|
König M, Osnes T, Bratland Å, Meling TR. Squamous Cell Carcinoma of the Paranasal Sinuses: A Single Center Experience. J Neurol Surg B Skull Base 2019; 81:664-672. [PMID: 33381371 DOI: 10.1055/s-0039-1694967] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Accepted: 07/03/2019] [Indexed: 01/19/2023] Open
Abstract
Objective Squamous cell carcinoma (SCC) of the paranasal sinuses is usually diagnosed at an advanced stage, making curative therapy difficult. The goal of this study was to evaluate the management and outcomes of patients with SCC treated at our institution. Methods In a population-based consecutive prospective cohort, we conducted an analysis of all patients treated for SCC between 1988 and 2017. Results A total of 72 patients were included, follow-up was 100%. Mean follow-up was 57 months for the entire cohort, and 108 months for patients with no evidence of disease. Eighty-two percent of all patients had high-stage (T4) disease. Fifty-seven patients underwent treatment with curative intent; consisting of surgery with or without oncologic treatment in 34, and of oncologic treatment only in 23 cases. Fifteen patients received palliative treatment. The rates of overall survival for the entire cohort were 55% at 2, 41% at 5, and 32% at 10 years, and corresponding disease-specific survival (DSS) rates were 55, 45, and 34%, respectively. DSS rates after surgical treatment with curative intent were 81% at 2, 65% at 5, and 54% at 10 years. Retromaxillary involvement and nonradical surgery were negative prognostic factors. Best survival was achieved with the combination of radical surgery and adjuvant oncologic treatment. Conclusion Surgical resection with a curative intent yielded 65% at 5-year DSS even in this cohort of patients with high-stage SCC and is still considered as the treatment of choice, preferably in combination with adjuvant radiation therapy and chemotherapy.
Collapse
Affiliation(s)
- Marton König
- Department of Neurosurgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.,Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Terje Osnes
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.,Department of Otorhinolaryngology, Head and Neck Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway
| | - Åse Bratland
- Department of Oncology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
| | - Torstein R Meling
- Department of Neurosurgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.,Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.,Service de Neurochirurgie, Département des Neurosciences Cliniques, Hopitaux Universitaires de Genève, Genève, Switzerland.,Faculty of Medicine, University of Geneva, Geneva, Switzerland
| |
Collapse
|
84
|
Zammar SG, Hennessy M, Warrick J, Goyal N, Zacharia BE. Leptomeningeal Carcinomatosis from Squamous Cell Carcinoma of the Ethmoid Sinus: A Case Report. Cureus 2019; 11:e5281. [PMID: 31576272 PMCID: PMC6764644 DOI: 10.7759/cureus.5281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Leptomeningeal carcinomatosis (LMC) is an end-stage disease with poor prognosis. This disease has not yet been reported with sinonasal carcinomatosis. We present a case of a patient who presented with posterior ethmoid/anterior cranial mass which turned out to be poorly differentiated squamous cell carcinoma (SCC). Later the patient presented with enhancement of the spinal roots and a lumbar puncture diagnosed the leptomeningeal spread of her primary disease. After intrathecal chemotherapy and palliative radiation, the patient failed to resist her disease seven months after the diagnosis. We present the first case report of leptomeningeal spread of sinonasal cancer. Although it seems rare, LMC should be on the differential of patients presenting with neurological deficits.
Collapse
Affiliation(s)
- Samer G Zammar
- Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, USA
| | - Max Hennessy
- Otolaryngology, Penn State Health Milton S. Hershey Medical Center, Hershey, USA
| | - Joshua Warrick
- Pathology, Penn State Health Milton S. Hershey Medical Center, Hershey, USA
| | - Neerav Goyal
- Otolaryngology, Penn State Health Milton S. Hershey Medical Center, Hershey, USA
| | - Brad E Zacharia
- Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, USA
| |
Collapse
|
85
|
Xiao R, Joshi RR, Husain Q, Cracchiolo JR, Lee N, Tsai J, Yu Y, Chen L, Kang JJ, McBride S, Riaz N, Roman BR, Ganly I, Tabar V, Gray ST, Cohen MA. Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach. Head Neck 2019; 41:3551-3563. [PMID: 31294897 DOI: 10.1002/hed.25873] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Revised: 06/03/2019] [Accepted: 06/26/2019] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Timely postoperative radiation therapy (RT) within 50 days of surgery for head and neck cancers provides a survival advantage. METHODS Using the National Cancer Database, we performed a propensity score-matched analysis comparing patients undergoing open or endoscopic surgery for squamous cell carcinoma (SCC) of the nasal cavity and paranasal sinuses from 2010 to 2015. RESULTS Among 168 pairs, patients undergoing endoscopic surgery had shorter time to surgery (24.2 vs 36.7 days, P < .001) and shorter postoperative time to RT (PTTR, 51.2 vs 58.4 days, P = .02). On multivariable linear regression, endoscopic surgery predicted shorter PTTR (β = -7.6, P = .01). Using the Kaplan-Meier method, patients in the longest PTTR quartile had decreased overall survival (OS; Q1 vs Q4, 3-year OS 76.5% vs 53.3%, P = .007), a durable finding when adjusted for covariates (Q1 vs Q4, HR 0.50, P = .008). CONCLUSIONS Patients undergoing endoscopic surgery for sinonasal SCC experience shorter PTTR. Shorter PTTR is associated with extended OS.
Collapse
Affiliation(s)
- Roy Xiao
- Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard University, Boston, Massachusetts
| | - Rohan R Joshi
- Department of Otolaryngology - Head and Neck Surgery, Case Western Reserve University, Cleveland, Ohio
| | - Qasim Husain
- Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard University, Boston, Massachusetts
| | - Jennifer R Cracchiolo
- Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Nancy Lee
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Jillian Tsai
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Yao Yu
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Linda Chen
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Jung J Kang
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Sean McBride
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Nadeem Riaz
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Benjamin R Roman
- Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Ian Ganly
- Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Viviane Tabar
- Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Stacey T Gray
- Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard University, Boston, Massachusetts
| | - Marc A Cohen
- Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
86
|
Kühn AL, Jalisi S, Nishino M, Ivanovic V. Biphenotypic sinonasal sarcoma – Description of radiologic, intraoperative and pathologic findings. OTOLARYNGOLOGY CASE REPORTS 2019. [DOI: 10.1016/j.xocr.2019.100113] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
87
|
Garcia de de Jesus K, Gupta S, Hwang RR, Vigoda I, Cisneros O. An Aggressive Case of Sinonasal Squamous Cell Carcinoma, Invasive to Bone, Arising Within Inverted Papilloma with Intracranial Extension: A Case Report. Cureus 2019; 11:e4508. [PMID: 31259117 PMCID: PMC6590862 DOI: 10.7759/cureus.4508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Abstract
Sinonasal squamous cell carcinoma represents a rare and aggressive disease. Clinical presentation usually mimics other benign entities and consequently this malignancy is seldom diagnosed in early stages. Surgical management, although is standard of care, is rarely amenable due to the structures involved, usually intracranially. This article encompasses a case report of squamous cell carcinoma involving the ethmoidal, maxillary, and sphenoid sinuses invasive to bone and extending intracranially.
Collapse
Affiliation(s)
| | - Sorab Gupta
- Oncology, St. Barnabas Hospital Health System / Albert Einstein College of Medicine, Bronx, USA
| | - Richard R Hwang
- Pathology, St. Barnabas Hospital Health System / Albert Einstein College of Medicine, Bronx, USA
| | - Ivette Vigoda
- Oncology, St. Barnabas Hospital Health System / Albert Einstein College of Medicine, Bronx, USA
| | - Oscar Cisneros
- Internal Medicine, St. Barnabas Hospital Health System / Albert Einstein College of Medicine, Bronx, USA
| |
Collapse
|
88
|
Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther 2019; 4:5. [PMID: 30854234 PMCID: PMC6405763 DOI: 10.1038/s41392-019-0038-9] [Citation(s) in RCA: 214] [Impact Index Per Article: 42.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 01/31/2019] [Accepted: 02/13/2019] [Indexed: 12/24/2022] Open
Abstract
Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic drivers in non-small cell lung cancer (NSCLC). However, unlike the classical EGFR L858R point mutation or exon 19 deletions, which represent the majority of EGFR mutations in NSCLC, low frequency EGFR exon 20 insertion mutations are associated with de novo resistance to targeted EGFR inhibitors and correlate with a poor patient prognosis. Here, we review the developments over the last 5 years in which pre-clinical studies, including elucidation of the crystal structure of an EGFR exon 20 insertion mutant kinase, have revealed a unique mechanism of kinase activation and steric conformation that define the lack of response of these EGFR mutations to clinically approved EGFR inhibitors. The recent development of several novel small molecule compounds that selectively inhibit EGFR exon 20 insertions holds promise for future therapeutic options that will be effective for patients with this molecular subtype of NSCLC.
Collapse
Affiliation(s)
- Simon Vyse
- Division of Molecular Pathology, The Institute of Cancer Research, London, SW3 6JB United Kingdom
| | - Paul H. Huang
- Division of Molecular Pathology, The Institute of Cancer Research, London, SW3 6JB United Kingdom
| |
Collapse
|
89
|
Franchi A, Bishop JA, Coleman H, Flucke U, Licitra LF, Pendás JLL, Stelow EB, Toner M, Weinreb I, Wenig BM, Thompson LDR. Data Set for the Reporting of Carcinomas of the Nasal Cavity and Paranasal Sinuses: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting. Arch Pathol Lab Med 2018; 143:424-431. [PMID: 30500298 DOI: 10.5858/arpa.2018-0404-sa] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The International Collaboration on Cancer Reporting was established to internationally unify and standardize the pathologic reporting of cancers based on collected evidence, as well as to allow systematic multi-institutional intercountry data collection to guide cancer care in the future. This data set has been developed by the collaborative efforts of an international multidisciplinary panel of experts involved in the care of patients with carcinomas of the nasal cavity and paranasal sinuses (sinonasal tract). The nasal cavity and paranasal sinuses (including frontal, sphenoid, ethmoid, and maxillary sinuses) comprise a very complex anatomic area of the head and neck, affected by a sometimes bewildering array of neoplasms. Management of malignancies in this anatomic region involves complex surgery because of the anatomic confines and close proximity to many vital structures. Given a multidisciplinary approach, the standardized reporting of the carcinomas that develop in this anatomic region include both required (core) and recommended (noncore) elements in pathology reporting in order to be able to identify critical prognostic factors, often requiring clinical and radiologic correlation. A summary of the International Collaboration on Cancer Reporting guidelines and clinically relevant elements, along with additional explanatory notes, are provided, based on evidentiary support from the literature, set in the context of practical application.
Collapse
Affiliation(s)
- Alessandro Franchi
- From the Department of Translational Research, University of Pisa, Pisa, Italy (Dr Franchi); the Department of Pathology, University of Texas Southwestern Medical Center, Dallas (Dr Bishop); the Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia (Dr Coleman); the Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands (Dr Flucke); the Head and Neck Medical Oncology Department, Fondazione International Collaboration on Cancer Reporting Istituto Nazionale dei Tumori, and University of Milan, Milan, Italy (Dr Licitra); the Department of Otolaryngology, Instituto Universitario de Oncología del Principado de Asturias, Centro de Investigación Biomédica en Red de Cancer, Hospital Universitario Central de Asturias, Oviedo, Spain (Dr Llorente Pendás); the Department of Pathology, University of Virginia, Charlottesville (Dr Stelow); St James and Dublin Dental Hospitals and Trinity College, Sir Patrick Dunne Research Laboratory, and St James Hospital, Dublin, Ireland (Dr Toner); the Department of Pathology, University Health Network, Toronto, Ontario, Canada (Dr Weinreb); the Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida (Dr Wenig); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills (Dr Thompson)
| | - Justin A Bishop
- From the Department of Translational Research, University of Pisa, Pisa, Italy (Dr Franchi); the Department of Pathology, University of Texas Southwestern Medical Center, Dallas (Dr Bishop); the Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia (Dr Coleman); the Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands (Dr Flucke); the Head and Neck Medical Oncology Department, Fondazione International Collaboration on Cancer Reporting Istituto Nazionale dei Tumori, and University of Milan, Milan, Italy (Dr Licitra); the Department of Otolaryngology, Instituto Universitario de Oncología del Principado de Asturias, Centro de Investigación Biomédica en Red de Cancer, Hospital Universitario Central de Asturias, Oviedo, Spain (Dr Llorente Pendás); the Department of Pathology, University of Virginia, Charlottesville (Dr Stelow); St James and Dublin Dental Hospitals and Trinity College, Sir Patrick Dunne Research Laboratory, and St James Hospital, Dublin, Ireland (Dr Toner); the Department of Pathology, University Health Network, Toronto, Ontario, Canada (Dr Weinreb); the Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida (Dr Wenig); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills (Dr Thompson)
| | - Hedley Coleman
- From the Department of Translational Research, University of Pisa, Pisa, Italy (Dr Franchi); the Department of Pathology, University of Texas Southwestern Medical Center, Dallas (Dr Bishop); the Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia (Dr Coleman); the Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands (Dr Flucke); the Head and Neck Medical Oncology Department, Fondazione International Collaboration on Cancer Reporting Istituto Nazionale dei Tumori, and University of Milan, Milan, Italy (Dr Licitra); the Department of Otolaryngology, Instituto Universitario de Oncología del Principado de Asturias, Centro de Investigación Biomédica en Red de Cancer, Hospital Universitario Central de Asturias, Oviedo, Spain (Dr Llorente Pendás); the Department of Pathology, University of Virginia, Charlottesville (Dr Stelow); St James and Dublin Dental Hospitals and Trinity College, Sir Patrick Dunne Research Laboratory, and St James Hospital, Dublin, Ireland (Dr Toner); the Department of Pathology, University Health Network, Toronto, Ontario, Canada (Dr Weinreb); the Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida (Dr Wenig); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills (Dr Thompson)
| | - Uta Flucke
- From the Department of Translational Research, University of Pisa, Pisa, Italy (Dr Franchi); the Department of Pathology, University of Texas Southwestern Medical Center, Dallas (Dr Bishop); the Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia (Dr Coleman); the Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands (Dr Flucke); the Head and Neck Medical Oncology Department, Fondazione International Collaboration on Cancer Reporting Istituto Nazionale dei Tumori, and University of Milan, Milan, Italy (Dr Licitra); the Department of Otolaryngology, Instituto Universitario de Oncología del Principado de Asturias, Centro de Investigación Biomédica en Red de Cancer, Hospital Universitario Central de Asturias, Oviedo, Spain (Dr Llorente Pendás); the Department of Pathology, University of Virginia, Charlottesville (Dr Stelow); St James and Dublin Dental Hospitals and Trinity College, Sir Patrick Dunne Research Laboratory, and St James Hospital, Dublin, Ireland (Dr Toner); the Department of Pathology, University Health Network, Toronto, Ontario, Canada (Dr Weinreb); the Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida (Dr Wenig); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills (Dr Thompson)
| | - Lisa F Licitra
- From the Department of Translational Research, University of Pisa, Pisa, Italy (Dr Franchi); the Department of Pathology, University of Texas Southwestern Medical Center, Dallas (Dr Bishop); the Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia (Dr Coleman); the Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands (Dr Flucke); the Head and Neck Medical Oncology Department, Fondazione International Collaboration on Cancer Reporting Istituto Nazionale dei Tumori, and University of Milan, Milan, Italy (Dr Licitra); the Department of Otolaryngology, Instituto Universitario de Oncología del Principado de Asturias, Centro de Investigación Biomédica en Red de Cancer, Hospital Universitario Central de Asturias, Oviedo, Spain (Dr Llorente Pendás); the Department of Pathology, University of Virginia, Charlottesville (Dr Stelow); St James and Dublin Dental Hospitals and Trinity College, Sir Patrick Dunne Research Laboratory, and St James Hospital, Dublin, Ireland (Dr Toner); the Department of Pathology, University Health Network, Toronto, Ontario, Canada (Dr Weinreb); the Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida (Dr Wenig); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills (Dr Thompson)
| | - José Luis Llorente Pendás
- From the Department of Translational Research, University of Pisa, Pisa, Italy (Dr Franchi); the Department of Pathology, University of Texas Southwestern Medical Center, Dallas (Dr Bishop); the Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia (Dr Coleman); the Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands (Dr Flucke); the Head and Neck Medical Oncology Department, Fondazione International Collaboration on Cancer Reporting Istituto Nazionale dei Tumori, and University of Milan, Milan, Italy (Dr Licitra); the Department of Otolaryngology, Instituto Universitario de Oncología del Principado de Asturias, Centro de Investigación Biomédica en Red de Cancer, Hospital Universitario Central de Asturias, Oviedo, Spain (Dr Llorente Pendás); the Department of Pathology, University of Virginia, Charlottesville (Dr Stelow); St James and Dublin Dental Hospitals and Trinity College, Sir Patrick Dunne Research Laboratory, and St James Hospital, Dublin, Ireland (Dr Toner); the Department of Pathology, University Health Network, Toronto, Ontario, Canada (Dr Weinreb); the Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida (Dr Wenig); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills (Dr Thompson)
| | - Edward B Stelow
- From the Department of Translational Research, University of Pisa, Pisa, Italy (Dr Franchi); the Department of Pathology, University of Texas Southwestern Medical Center, Dallas (Dr Bishop); the Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia (Dr Coleman); the Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands (Dr Flucke); the Head and Neck Medical Oncology Department, Fondazione International Collaboration on Cancer Reporting Istituto Nazionale dei Tumori, and University of Milan, Milan, Italy (Dr Licitra); the Department of Otolaryngology, Instituto Universitario de Oncología del Principado de Asturias, Centro de Investigación Biomédica en Red de Cancer, Hospital Universitario Central de Asturias, Oviedo, Spain (Dr Llorente Pendás); the Department of Pathology, University of Virginia, Charlottesville (Dr Stelow); St James and Dublin Dental Hospitals and Trinity College, Sir Patrick Dunne Research Laboratory, and St James Hospital, Dublin, Ireland (Dr Toner); the Department of Pathology, University Health Network, Toronto, Ontario, Canada (Dr Weinreb); the Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida (Dr Wenig); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills (Dr Thompson)
| | - Mary Toner
- From the Department of Translational Research, University of Pisa, Pisa, Italy (Dr Franchi); the Department of Pathology, University of Texas Southwestern Medical Center, Dallas (Dr Bishop); the Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia (Dr Coleman); the Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands (Dr Flucke); the Head and Neck Medical Oncology Department, Fondazione International Collaboration on Cancer Reporting Istituto Nazionale dei Tumori, and University of Milan, Milan, Italy (Dr Licitra); the Department of Otolaryngology, Instituto Universitario de Oncología del Principado de Asturias, Centro de Investigación Biomédica en Red de Cancer, Hospital Universitario Central de Asturias, Oviedo, Spain (Dr Llorente Pendás); the Department of Pathology, University of Virginia, Charlottesville (Dr Stelow); St James and Dublin Dental Hospitals and Trinity College, Sir Patrick Dunne Research Laboratory, and St James Hospital, Dublin, Ireland (Dr Toner); the Department of Pathology, University Health Network, Toronto, Ontario, Canada (Dr Weinreb); the Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida (Dr Wenig); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills (Dr Thompson)
| | - Ilan Weinreb
- From the Department of Translational Research, University of Pisa, Pisa, Italy (Dr Franchi); the Department of Pathology, University of Texas Southwestern Medical Center, Dallas (Dr Bishop); the Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia (Dr Coleman); the Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands (Dr Flucke); the Head and Neck Medical Oncology Department, Fondazione International Collaboration on Cancer Reporting Istituto Nazionale dei Tumori, and University of Milan, Milan, Italy (Dr Licitra); the Department of Otolaryngology, Instituto Universitario de Oncología del Principado de Asturias, Centro de Investigación Biomédica en Red de Cancer, Hospital Universitario Central de Asturias, Oviedo, Spain (Dr Llorente Pendás); the Department of Pathology, University of Virginia, Charlottesville (Dr Stelow); St James and Dublin Dental Hospitals and Trinity College, Sir Patrick Dunne Research Laboratory, and St James Hospital, Dublin, Ireland (Dr Toner); the Department of Pathology, University Health Network, Toronto, Ontario, Canada (Dr Weinreb); the Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida (Dr Wenig); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills (Dr Thompson)
| | - Bruce M Wenig
- From the Department of Translational Research, University of Pisa, Pisa, Italy (Dr Franchi); the Department of Pathology, University of Texas Southwestern Medical Center, Dallas (Dr Bishop); the Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia (Dr Coleman); the Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands (Dr Flucke); the Head and Neck Medical Oncology Department, Fondazione International Collaboration on Cancer Reporting Istituto Nazionale dei Tumori, and University of Milan, Milan, Italy (Dr Licitra); the Department of Otolaryngology, Instituto Universitario de Oncología del Principado de Asturias, Centro de Investigación Biomédica en Red de Cancer, Hospital Universitario Central de Asturias, Oviedo, Spain (Dr Llorente Pendás); the Department of Pathology, University of Virginia, Charlottesville (Dr Stelow); St James and Dublin Dental Hospitals and Trinity College, Sir Patrick Dunne Research Laboratory, and St James Hospital, Dublin, Ireland (Dr Toner); the Department of Pathology, University Health Network, Toronto, Ontario, Canada (Dr Weinreb); the Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida (Dr Wenig); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills (Dr Thompson)
| | - Lester D R Thompson
- From the Department of Translational Research, University of Pisa, Pisa, Italy (Dr Franchi); the Department of Pathology, University of Texas Southwestern Medical Center, Dallas (Dr Bishop); the Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia (Dr Coleman); the Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands (Dr Flucke); the Head and Neck Medical Oncology Department, Fondazione International Collaboration on Cancer Reporting Istituto Nazionale dei Tumori, and University of Milan, Milan, Italy (Dr Licitra); the Department of Otolaryngology, Instituto Universitario de Oncología del Principado de Asturias, Centro de Investigación Biomédica en Red de Cancer, Hospital Universitario Central de Asturias, Oviedo, Spain (Dr Llorente Pendás); the Department of Pathology, University of Virginia, Charlottesville (Dr Stelow); St James and Dublin Dental Hospitals and Trinity College, Sir Patrick Dunne Research Laboratory, and St James Hospital, Dublin, Ireland (Dr Toner); the Department of Pathology, University Health Network, Toronto, Ontario, Canada (Dr Weinreb); the Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida (Dr Wenig); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills (Dr Thompson)
| |
Collapse
|
90
|
Sasaki E, Nishikawa D, Hanai N, Hasegawa Y, Yatabe Y. Sinonasal squamous cell carcinoma and EGFR mutations: a molecular footprint of a benign lesion. Histopathology 2018; 73:953-962. [PMID: 30117182 DOI: 10.1111/his.13732] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Accepted: 08/17/2018] [Indexed: 01/17/2023]
Abstract
AIMS Molecular targeted therapy against EGFR kinase domain mutations has been successfully established for lung cancer. These mutations have now also been reported in head and neck tumours, particularly in inverted sinonasal papillomas (ISPs). The aim of this study was to clarify the spectrum of EGFR mutations in head and neck squamous cell carcinomas and papillomas. METHODS AND RESULTS We examined EGFR mutations in 288 head and neck squamous cell carcinomas and 58 head and neck papillomas or polyps. EGFR mutations were detected in 24 (30%) of 80 sinonasal squamous cell carcinomas (SNSCCs) and in 19 (90%) of 21 ISPs. Notably, 15 (88%) of 17 SNSCCs that developed along with ISPs harboured EGFR mutations in both components, whereas EGFR mutations were detected in nine (14%) of 63 SNSCCs without any papilloma component. Analysis to detect other known driver oncogene mutations - KRAS, BRAF and HER2 - was also performed; none of these mutations was detected in SNSCCs. The other 208 non-sinonasal carcinomas and 37 non-ISP head and neck papillomas or polyps did not harbour EGFR mutations. CONCLUSIONS Taken together with the specific involvement of EGFR mutations in ISP, a molecular benign lesion trail suggests that 26 (33%) of 80 SNSCCs developed in association with an ISP. SNSCCs with EGFR mutations may be biologically distinct among head and neck cancers.
Collapse
Affiliation(s)
- Eiichi Sasaki
- Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Daisuke Nishikawa
- Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Nobuhiro Hanai
- Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Yasuhisa Hasegawa
- Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.,Department of Head and Neck Surgery, Asahi University Hospital, Gifu, Japan
| | - Yasushi Yatabe
- Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
| |
Collapse
|
91
|
Kuijpens JHLP, Louwman MWJ, Takes R, Slootweg PJ, Burdorf A, van Dijk BAC. Sinonasal cancer in The Netherlands: Follow-up of a population-based study 1989-2014 and incidence of occupation-related adenocarcinoma. Head Neck 2018; 40:2462-2468. [DOI: 10.1002/hed.25374] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Revised: 03/09/2018] [Accepted: 05/22/2018] [Indexed: 01/09/2023] Open
Affiliation(s)
| | - Marieke W. J. Louwman
- Comprehensive Cancer Centre The Netherlands (IKNL), Department of Research; Utrecht The Netherlands
| | - Robert Takes
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery; Radboud University Medical Centre; Nijmegen The Netherlands
| | - Piet J. Slootweg
- Department of Pathology; Radboud University Medical Centre; Nijmegen The Netherlands
| | - Alex Burdorf
- Department of Public Health; Erasmus Medical Centre; Rotterdam The Netherlands
| | - Boukje A. C. van Dijk
- Comprehensive Cancer Centre The Netherlands (IKNL), Department of Research; Utrecht The Netherlands
- University of Groningen, University Medical Center Groningen, Department of Epidemiology; Groningen The Netherlands
| |
Collapse
|
92
|
Zhao Y, Wang X. miR-34a targets BCL-2 to suppress the migration and invasion of sinonasal squamous cell carcinoma. Oncol Lett 2018; 16:6566-6572. [PMID: 30405796 PMCID: PMC6202510 DOI: 10.3892/ol.2018.9427] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Accepted: 08/28/2018] [Indexed: 12/16/2022] Open
Abstract
Sinonasal squamous cell carcinomas (SN-SCC) are rare tumors with low survival rate. It was reported that miR-34a expression is low in many cancers and acted as a tumor suppressor. But the biological function of miR-34a in SN-SCC has hardly been reported. Therefore, we explored the role and underlying mechanism of miR-34a in the migration and invasion of SN-SCC. Western blot analysis and RT-PCR were carried out to examine B-cell lymphoma-2 (BCL-2) and miR-34a expression in SN-SCC. Transwell assay was performed to test the SN-SCC migratory and invasive ability. Luciferase reporter assay was carried out to verify the target of miR-34a. Results demonstrated that miR-34a expression was lower in SN-SCC tissues and cells than normal SN-SCC. Re-expression of miR-34a inhibited cell migration and invasion, while had the opposite effect on inhibition of miR-34a. We also found that BCL-2 expression was higher in SN-SCC and silencing BCL-2 curbed the development of SN-SCC. BCL-2 was found to be a target of miR-34a and negatively correlated with miR-34a expression. Furthermore, BCL-2 attenuated the miR-34a inhibitory effect on SN-SCC cell migration and invasion. In short, these data demonstrated that miR-34a inhibited SN-SCC cell migration and invasion through targeting BCL-2.
Collapse
Affiliation(s)
- Yigang Zhao
- Department of Otolaryngology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China
| | - Xianzhi Wang
- Department of Otolaryngology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China
| |
Collapse
|
93
|
Sjöstedt S, Jensen DH, Jakobsen KK, Grønhøj C, Geneser C, Karnov K, Specht L, Agander TK, von Buchwald C. Incidence and survival in sinonasal carcinoma: a Danish population-based, nationwide study from 1980 to 2014. Acta Oncol 2018; 57:1152-1158. [PMID: 29578367 DOI: 10.1080/0284186x.2018.1454603] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND Sinonasal cancers are rare and comprise <1% of all malignancies. This study describes incidence and survival in sinonasal carcinomas in Denmark from 1980 to 2014. METHODS All patients registered in the Danish Cancer Registry in the period were included. Age-adjusted incidence rate, average annual percentage change, and relative survival were calculated. Age-period-cohort models were constructed. RESULTS 1,720 patients with sinonasal carcinoma (median age 67 years, 63% males) were identified. There was no significant change in age-adjusted incidence; 0.70 in 1980 to 0.43 per 100,000 in 2014 (p > .05). Relative 5- and 10-year survival were 52% and 40% for men, 58% and 42% for women. An increase in 5-year survival from 1980 to 2014 from 46% to 65% (p < .05) was found. Nasal carcinomas had a significantly better relative survival compared to sinus carcinoma, as did squamous cell carcinomas when compared to neuroendocrine malignancies. CONCLUSION In Denmark between 1980 and 2014, the incidence of sinonasal carcinomas has been stable and the relative survival has increased significantly.
Collapse
Affiliation(s)
- Sannia Sjöstedt
- Department of Otorhinolaryngology Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen Oe, Denmark
| | - David Hebbelstrup Jensen
- Department of Otorhinolaryngology Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen Oe, Denmark
| | - Kathrine Kronberg Jakobsen
- Department of Otorhinolaryngology Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen Oe, Denmark
| | - Christian Grønhøj
- Department of Otorhinolaryngology Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen Oe, Denmark
| | - Charlotte Geneser
- Department of Otorhinolaryngology Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen Oe, Denmark
| | - Kirstine Karnov
- Department of Otorhinolaryngology Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen Oe, Denmark
| | - Lena Specht
- Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen Oe, Denmark
| | | | - Christian von Buchwald
- Department of Otorhinolaryngology Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen Oe, Denmark
| |
Collapse
|
94
|
Jain S, Li Y, Kuan EC, Tajudeen BA, Batra PS. Prognostic Factors in Paranasal Sinus Squamous Cell Carcinoma and Adenocarcinoma: A SEER Database Analysis. J Neurol Surg B Skull Base 2018; 80:258-263. [PMID: 31143568 DOI: 10.1055/s-0038-1669420] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2017] [Accepted: 07/07/2018] [Indexed: 12/12/2022] Open
Abstract
Background Outcome studies on sinonasal malignancy are limited to retrospective case series, often with inclusion of diverse histology and short follow-up. The objective of this study was to identify key predictive variables that independently impact survival for paranasal sinus squamous cell carcinoma (SCC) and adenocarcinoma (AC) and to compare these variables in the context of these two distinct clinicopathologic entities. Methods: Analysis was conducted using the Surveillance, Epidemiology, and End Results database from 1973 to 2012 to identify key variables that impact survival for SCC and AC. Results A total of 3,714 cases were included. There were 2,895 SCC cases and 819 AC cases. The mean age at diagnosis was 64.1 years. The male to female ratio for SCC and AC was 1.85 and 1.04, respectively. Patients with SCC and AC were most often diagnosed with stage IV disease in 61.8 and 63.4% of cases, respectively. The majority of patients received combined surgery and radiation (52% for SCC and 43.1% for AC). For SCC, increased age ( p < 0.001) and stage ( p < 0.001) were negative predictors, and surgery improved survival ( p < 0.001) on multivariate analysis. For AC, prognostic factors associated with worse survival include increased age ( p < 0.001) and grade ( p < 0.001) on multivariate analysis. Overall survival was significantly higher in AC compared with SCC at 5 years ( p = 0.001). Conclusion SCC and AC of the paranasal sinuses are both aggressive malignancies with poor survival. For both histological subtypes, increased age predicts worse survival and grade also closely links to survival in AC. These data have important potential implications for treatment planning and pretreatment counseling.
Collapse
Affiliation(s)
- Sumit Jain
- Department of Anesthesia and Critical Care, University of Chicago, Chicago, Illinois, United States
| | - Yan Li
- Department of Otolaryngology, Rush University, Chicago, Illinois, United States
| | - Edward C Kuan
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, United States
| | - Bobby A Tajudeen
- Department of Otorhinolaryngology - Head and Neck Surgery, Center for Skull Base and Pituitary Surgery, Rush University Medical Center, Chicago, Illinois, United States
| | - Pete S Batra
- Department of Otorhinolaryngology - Head and Neck Surgery, Center for Skull Base and Pituitary Surgery, Rush University Medical Center, Chicago, Illinois, United States
| |
Collapse
|
95
|
Lobo BC, D'Anza B, Farlow JL, Tang D, Woodard TD, Ting JY, Sindwani R. Outcomes of sinonasal squamous cell carcinoma with and without association of inverted papilloma: A multi-institutional analysis. Am J Rhinol Allergy 2018; 31:305-309. [PMID: 28859706 DOI: 10.2500/ajra.2017.31.4470] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
INTRODUCTION Sinonasal squamous cell carcinoma (SCC) accounts for <1% of all malignancies but represents 70% of sinonasal cancer. Up to 10% of SCCs are associated with inverted papilloma (IPSCC). Studies that compare patients, treatment, and outcomes of SCC and IPSCC are absent in the literature. METHODS A retrospective review of patients with SCC and those with IPSCC at Cleveland Clinic and Indiana University from 1995 to 2015. The records were analyzed for demographics, tumor characteristics, treatment, and outcomes. RESULTS The study comprised 117 patients with SCC, of whom, 29 had IPSCC. The mean age at diagnosis was similar: 63 and 64 years for patients with SCC and patients with IPSCC, respectively; with female patients representing 36% and 34%, respectively (p > 0.99).Smokers represented 64% of the patients with SCC and 55% of patients with IPSCC (p = 0.3); excessive alcohol intake was noted in 16% of the patients with SCC and 21% of the patients with IPSCC (p = 0.56).The maxillary sinus was most commonly involved, followed by the nasal cavity (51% versus 35% SCC, 45% versus 38% IPSCC). Frontal ethmoid and sphenoid sinuses contained primary tumors only in patients with SCC. Upfront treatment was surgery in 84% of patients with SCC and 97% of patients with IPSCC (p = 0.18); 68 and 55% received radiation, respectively, and 25 and 21% received chemotherapy, respectively.Overall survival averaged 5.5 and 3.4 years for patients with SCC and patients with IPSCC, respectively (p = 0.12); disease-free survival was 4.8 and 2.9 years, respectively (p = 0.18). Nodal metastasis was more likely in patients with SCC (18 versus 0%; p = 0.02). When divided into high- and low-stage disease: more common nodal metastases were demonstrated in high-stage SCC than in low-stage disease (p = 0.03). Overall survival was decreased between high- and low-grade disease but not when subdivided between SCC and IPSCC. CONCLUSION Although SCC with and without IP association are considered different diseases, their demographics and outcomes seem similar. Nodal metastasis was noted to be higher in the SCC cohort, which may indicate different tumor biology. Further study is warranted.
Collapse
Affiliation(s)
- Brian C Lobo
- Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | | | | | | | | | | | | |
Collapse
|
96
|
Praveena NM, Maragathavalli G. Carcinoma of the Maxillary Antrum: A Case Report. Cureus 2018; 10:e2614. [PMID: 30027006 PMCID: PMC6044491 DOI: 10.7759/cureus.2614] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Accepted: 05/13/2018] [Indexed: 11/18/2022] Open
Abstract
Maxillary sinus squamous cell carcinoma is an aggressive tumor, usually diagnosed at an advanced stage and most patients present with very poor prognosis and survival rate. We report a case of the patient who presented with pain and swelling in the left maxillary region. Due to the advanced stage at which it was presented and the involvement of vital structures, the patient was subjected to palliative treatment. The symptoms of maxillary sinus carcinoma can be non-specific, resulting in late diagnosis. It is pertinent for the maxillofacial physician to be aware of these sinus pathologies and arrive at an early diagnosis to improve the survival rate.
Collapse
Affiliation(s)
- N M Praveena
- Oral Medicine and Radiology, Thai Moogambigai Dental College & Hospital, Mugappair, IND
| | - Gopla Maragathavalli
- Oral Medicine and Radiology, Saveetha Dental College and Hospital, Saveetha University, Chennai, IND
| |
Collapse
|
97
|
Ganti A, Plitt MA, Kuan EC, Kuhar HN, Batra PS, Tajudeen BA. Risk of second primary malignancy in patients with sinonasal tumors: a population-based cohort study. Int Forum Allergy Rhinol 2018; 8:756-762. [DOI: 10.1002/alr.22092] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2017] [Revised: 12/19/2017] [Accepted: 01/10/2018] [Indexed: 12/19/2022]
Affiliation(s)
- Ashwin Ganti
- Rush Medical College; Rush University; Chicago IL
| | - Max A. Plitt
- Department of Otorhinolaryngology-Head and Neck Surgery; Rush University Medical Center; Chicago IL
- Rush Center for Skull Base and Pituitary Surgery; Rush University Medical Center; Chicago IL
| | - Edward C. Kuan
- Division of Rhinology, Department of Otorhinolaryngology-Head and Neck Surgery; University of Pennsylvania; Philadelphia PA
| | | | - Pete S. Batra
- Department of Otorhinolaryngology-Head and Neck Surgery; Rush University Medical Center; Chicago IL
- Rush Center for Skull Base and Pituitary Surgery; Rush University Medical Center; Chicago IL
| | - Bobby A. Tajudeen
- Department of Otorhinolaryngology-Head and Neck Surgery; Rush University Medical Center; Chicago IL
- Rush Center for Skull Base and Pituitary Surgery; Rush University Medical Center; Chicago IL
| |
Collapse
|
98
|
Ansa BE, Coughlin SS, Alema-Mensah E, Smith SA. Evaluation of Colorectal Cancer Incidence Trends in the United States (2000-2014). J Clin Med 2018; 7:jcm7020022. [PMID: 29385768 PMCID: PMC5852438 DOI: 10.3390/jcm7020022] [Citation(s) in RCA: 62] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2017] [Revised: 01/23/2018] [Accepted: 01/23/2018] [Indexed: 12/18/2022] Open
Abstract
Colorectal cancer (CRC) incidence rates have declined in recent years for people of all races/ethnicities; however, the extent to which the decrease varies annually by demographic and disease-related characteristics is largely unknown. This study examines trends and annual percent change (APC) in the incidence among persons diagnosed with CRC in the United States of America from 2000-2014. The data obtained from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program were analyzed, and all persons (N = 577,708) with malignant CRC recorded in the SEER 18 database from 2000 to 2014 were characterized according to sex, race, age at diagnosis, disease site and stage. Incidence rates and APC were calculated for the entire study period. Overall, the incidence rate of CRC decreased from 54.5 in 2000 to 38.6 per 100,000 in 2014, with APC = -2.66 (p < 0.0001). Decline in rates was most profound between 2008 and 2011 from 46.0 to 40.7 per 100,000 (APC = -4.04; p < 0.0001). Rates were higher for males (vs. females; rate ratio (RR) = 1.33) and for blacks (vs. whites; RR = 1.23). Proximal colon cancers at the localized stage were the predominant cancers. An increase in rate was observed among people younger than 50 years (6.6 per 100,000, APC= 1.5). The annual rate of CRC has decreased over time. However, the development and implementation of interventions that further reduce the disparities among demographic and disease-related subgroups are warranted.
Collapse
Affiliation(s)
- Benjamin E Ansa
- Institute of Public and Preventive Health, Augusta University, Augusta, GA 30912, USA.
| | - Steven S Coughlin
- Department of Clinical and Digital Health Sciences, College of Allied Health Sciences, Augusta University, Augusta, GA 30912, USA.
| | - Ernest Alema-Mensah
- Department of Community Health and Preventive Medicine, Morehouse School of Medicine, Atlanta, GA 30310, USA.
| | - Selina A Smith
- Department of Family Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
| |
Collapse
|
99
|
Kılıç S, Kılıç SS, Baredes S, Chan Woo Park R, Mahmoud O, Suh JD, Gray ST, Eloy JA. Comparison of endoscopic and open resection of sinonasal squamous cell carcinoma: a propensity score-matched analysis of 652 patients. Int Forum Allergy Rhinol 2017; 8:421-434. [DOI: 10.1002/alr.22040] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Revised: 10/20/2017] [Accepted: 10/24/2017] [Indexed: 02/03/2023]
Affiliation(s)
- Suat Kılıç
- Department of Otolaryngology-Head and Neck Surgery; Rutgers New Jersey Medical School; Newark NJ
| | - Sarah S. Kılıç
- Department of Radiation Oncology; Rutgers New Jersey Medical School; Newark NJ
| | - Soly Baredes
- Department of Otolaryngology-Head and Neck Surgery; Rutgers New Jersey Medical School; Newark NJ
- Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey; Rutgers New Jersey Medical School; Newark NJ
| | - Richard Chan Woo Park
- Department of Otolaryngology-Head and Neck Surgery; Rutgers New Jersey Medical School; Newark NJ
| | - Omar Mahmoud
- Department of Radiation Oncology; Rutgers New Jersey Medical School; Newark NJ
| | - Jeffrey D. Suh
- Department of Head and Neck Surgery; University of California at Los Angeles David Geffen School of Medicine; Los Angeles CA
| | - Stacey T. Gray
- Department of Otolaryngology; Harvard Medical School; Boston MA
- Department of Otolaryngology; Massachusetts Eye and Ear; Boston MA
| | - Jean Anderson Eloy
- Department of Otolaryngology-Head and Neck Surgery; Rutgers New Jersey Medical School; Newark NJ
- Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey; Rutgers New Jersey Medical School; Newark NJ
- Department of Neurological Surgery; Rutgers New Jersey Medical School; Newark NJ
- Department of Ophthalmology and Visual Science; Rutgers New Jersey Medical School; Newark NJ
| |
Collapse
|
100
|
Zhou AH, Chung SY, Patel VR, Unsal AA, Hsueh WD, Baredes S, Eloy JA. Do geographic differences or socioeconomic disparities affect survival in sinonasal squamous cell carcinoma? Int Forum Allergy Rhinol 2017; 7:1195-1200. [DOI: 10.1002/alr.22029] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Accepted: 09/19/2017] [Indexed: 01/09/2023]
Affiliation(s)
- Albert H. Zhou
- Department of Otolaryngology-Head and Neck Surgery; Rutgers New Jersey Medical School; Newark NJ
| | - Sei Y. Chung
- Department of Otolaryngology-Head and Neck Surgery; Rutgers New Jersey Medical School; Newark NJ
| | - Varesh R. Patel
- Department of Otolaryngology-Head and Neck Surgery; Rutgers New Jersey Medical School; Newark NJ
| | - Aykut A. Unsal
- Department of Otolaryngology and Facial Plastic Surgery; Rowan University School of Osteopathic Medicine; Stratford NJ
| | - Wayne D. Hsueh
- Department of Otolaryngology-Head and Neck Surgery; Rutgers New Jersey Medical School; Newark NJ
| | - Soly Baredes
- Department of Otolaryngology-Head and Neck Surgery; Rutgers New Jersey Medical School; Newark NJ
- Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey; Rutgers New Jersey Medical School; Newark NJ
| | - Jean Anderson Eloy
- Department of Otolaryngology-Head and Neck Surgery; Rutgers New Jersey Medical School; Newark NJ
- Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey; Rutgers New Jersey Medical School; Newark NJ
- Department of Neurological Surgery; Rutgers New Jersey Medical School; Newark NJ
- Department of Ophthalmology and Visual Science; Rutgers New Jersey Medical School; Newark NJ
| |
Collapse
|